<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1186/s12951-022-01310-2</query><apiKey>87ba7cb21f89ce78154df796840621f4</apiKey><result><total>1</total><start>1</start><pageLength>2</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="research-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="publisher-id">12951</journal-id><journal-title-group><journal-title>Journal of Nanobiotechnology</journal-title><abbrev-journal-title abbrev-type="publisher">J Nanobiotechnol</abbrev-journal-title></journal-title-group><issn pub-type="epub">1477-3155</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s12951-022-01310-2</article-id><article-id pub-id-type="manuscript">1310</article-id><article-id pub-id-type="doi">10.1186/s12951-022-01310-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Multifunctional photodynamic/photothermal nano-agents for the treatment of oral leukoplakia</article-title></title-group><contrib-group><contrib contrib-type="author" id="Au1"><name><surname>Lin</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au2"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3880-7868</contrib-id><name><surname>Song</surname><given-names>Chuanhui</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" id="Au3"><name><surname>Wei</surname><given-names>Zheng</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" id="Au4"><name><surname>Zou</surname><given-names>Huihui</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au5"><name><surname>Han</surname><given-names>Shengwei</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au6"><name><surname>Cao</surname><given-names>Zichen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au7"><name><surname>Zhang</surname><given-names>Xinyu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au8"><name><surname>Zhang</surname><given-names>Guorong</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au9"><name><surname>Ran</surname><given-names>Jianchuan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au10"><name><surname>Cai</surname><given-names>Yu</given-names></name><address><email>iamycai@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="corresp" rid="IDs12951022013102_cor10">k</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au11"><name><surname>Han</surname><given-names>Wei</given-names></name><address><email>doctorhanwei@hotmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="corresp" rid="IDs12951022013102_cor11">m</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.41156.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2314 964X</institution-id><institution content-type="org-division">Department of Oral Medicine, Nanjing Stomatological Hospital</institution><institution content-type="org-name">Medical School of Nanjing University</institution></institution-wrap><addr-line content-type="street">30 Zhongyang Road</addr-line><addr-line content-type="postcode">210008</addr-line><addr-line content-type="city">Nanjing</addr-line><country country="CN">China</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.41156.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2314 964X</institution-id><institution content-type="org-division">Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital</institution><institution content-type="org-name">Medical School of Nanjing University</institution></institution-wrap><addr-line content-type="street">No 30 Zhongyang Road</addr-line><addr-line content-type="postcode">210008</addr-line><addr-line content-type="city">Nanjing</addr-line><country country="CN">China</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.417401.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 6507</institution-id><institution content-type="org-division">Center for Rehabilitation Medicine, Rehabilitation &amp; Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine</institution><institution content-type="org-name">Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College)</institution></institution-wrap><addr-line content-type="postcode">310014</addr-line><addr-line content-type="city">Hangzhou</addr-line><addr-line content-type="state">Zhejiang</addr-line><country country="CN">China</country></aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.41156.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2314 964X</institution-id><institution content-type="org-division">Central Laboratory of Stomatology, Nanjing Stomatological Hospital</institution><institution content-type="org-name">Medical School of Nanjing University</institution></institution-wrap><addr-line content-type="street">No 30 Zhongyang Road</addr-line><addr-line content-type="postcode">210008</addr-line><addr-line content-type="city">Nanjing</addr-line><country country="CN">China</country></aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.428392.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1800 1685</institution-id><institution content-type="org-division">Institute of Translational Medicine</institution><institution content-type="org-name">The Affiliated Drum Tower Hospital of Nanjing University Medical School</institution></institution-wrap><addr-line content-type="postcode">210008</addr-line><addr-line content-type="city">Nanjing</addr-line><country country="CN">China</country></aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.41156.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2314 964X</institution-id><institution content-type="org-division">Pediatric Dentistry, Nanjing Stomatology Hospital</institution><institution content-type="org-name">Medical School of Nanjing University</institution></institution-wrap><addr-line content-type="street">No 30 Zhongyang road</addr-line><addr-line content-type="postcode">210008</addr-line><addr-line content-type="city">Nanjing</addr-line><country country="CN">China</country></aff></contrib-group><author-notes><fn fn-type="con"><p>Lin Lin and Chuanhui Song contributed equally to this work</p></fn><corresp id="IDs12951022013102_cor10"><label>k</label><email>iamycai@163.com</email></corresp><corresp id="IDs12951022013102_cor11"><label>m</label><email>doctorhanwei@hotmail.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>4</day><month>3</month><year>2022</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2022</year></pub-date><volume>20</volume><issue seq="106">1</issue><elocation-id>106</elocation-id><history><date date-type="registration"><day>20</day><month>2</month><year>2022</year></date><date date-type="received"><day>29</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2022</year></date><date date-type="online"><day>4</day><month>3</month><year>2022</year></date></history><permissions><copyright-statement content-type="compact">© The Author(s) 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xlink:href="http://creativecommons.org/publicdomain/zero/1.0/" ext-link-type="uri">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract xml:lang="en" id="Abs1"><title>Abstract</title><sec><p id="Par1">Oral leukoplakia (OLK) has gained extensive attention because of the potential risk for malignant transformation. Photosensitizers (PSs) played an indispensable role in the photodynamic therapy (PDT) of OLK, but the poor light sensitivity greatly hampered its clinical application. Herein, a novel organic photosensitive ITIC-Th nanoparticles (ITIC-Th NPs) were developed for OLK photodynamic/photothermal therapy (PTT). ITIC-Th NPs present both high photothermal conversion efficiency (~ 38%) and suitable reactive oxygen species (ROS) generation ability under 660 nm laser irradiation, making them possess excellent PDT and PTT capability. In 4-nitroquinoline 1-oxide (4NQO)-induced oral precancerous animal models, ITIC-Th NPs effectively suppress the OLK's cancerization without apparent topical or systemic toxicity in vivo. This study offers a promising therapeutic strategy for PDT and PTT in OLK treatment, and this study is the first interdisciplinary research in the field of multimodal therapy for OLK.</p></sec><sec id="ASec1"><title>Graphical Abstract</title><p id="Par500"><fig id="Figa" position="anchor"><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1310_Figa_HTML.png" position="anchor" id="MO1"/></fig></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Nanomedicine</kwd><kwd>Photodynamic therapy</kwd><kwd>Oral leukoplakia</kwd><kwd>Tumor</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">http://dx.doi.org/10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">82002864</award-id><principal-award-recipient><name><surname>Han</surname><given-names>Shengwei</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution>Natural Science Foundation of Jiangsu Province</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">http://dx.doi.org/10.13039/501100004608</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">BK20191121</award-id><award-id award-type="FundRef grant">BK20210033</award-id><principal-award-recipient><name><surname>Wei</surname><given-names>Zheng</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution>the Project of Invigorating Health Care through Science, Technology, and Education Jiangsu Provincial Medical Youth Talent</institution></institution-wrap></funding-source><award-id award-type="FundRef grant">QNRC2016121</award-id><principal-award-recipient><name><surname>Han</surname><given-names>Wei</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution>China Postdoctoral Science Foundation</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">http://dx.doi.org/10.13039/501100002858</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">2021TQ0145</award-id><principal-award-recipient><name><surname>Song</surname><given-names>Chuanhui</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution>Nanjing Clinical Research Center for Oral Diseases</institution></institution-wrap></funding-source><award-id award-type="FundRef grant">2019060009</award-id><principal-award-recipient><name><surname>Han</surname><given-names>Wei</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>BioMed Central</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>106</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2022</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2022</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>Yes</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2022</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>2</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>20</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>ArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/12951_2022_Article_1310.pdf</meta-value></custom-meta><custom-meta><meta-name>pdf-type</meta-name><meta-value>Typeset</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Chemistry</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Biotechnology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Nanotechnology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Molecular Medicine</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Chemistry and Materials Science</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="ESMHint"><title>Supplementary Information</title><p>The online version contains supplementary material available at <ext-link xlink:href="10.1186/s12951-022-01310-2" ext-link-type="doi">https://doi.org/10.1186/s12951-022-01310-2</ext-link>.</p></notes></front><body><sec id="Sec1"><title>Introduction</title><p id="Par41">Oral squamous cell carcinoma (OSCC) accounts for more than 90% of oral malignancies, and most OSCC develops from oral precancerous lesions, which are collectively referred to as potentially malignant disorders (OPMDs) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. According to the definition of the World Health Organization (WHO), oral leukoplakia (OLK) is one of the most common OPMDs in oral mucosa, which is now defined as white irreversible and non-scratchable plaques that are at risk of turning into cancer [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. To date, the prevalence rate of OLK is 3.5% (range: 0.13–34.0%), among which 4–13% could be transformed into malignant disease [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The presence and grading of epithelial dysplasia are the most commonly used prognostic factors to predict malignant transformation, which might be significantly reduced but not eliminated after the excision. Thus, OLK is an excellent clinical model for examining cancer prevention strategies [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par42">Photodynamic therapy (PDT), as a minimally invasive approach, plays an indispensable role in the management of OLK. Unlike surgical resection, PDT is highly selective and repeatable with minimal scarring and is particularly valuable in regions with underlying functional structures [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. 5-aminolevulinic acid (5-ALA) is a water-soluble photosensitizer widely used to treat OPMDs, especially OLK. It can be administered intravenously, orally, or locally [<xref ref-type="bibr" rid="CR12">12</xref>]. It is a precursor of porphyrins, which can't produce reactive oxygen species (ROS) by itself. After exogenous 5-ALA enters cells, it converts to porphyrin IX (PpIX) through the porphyrin-haem pathway, ROS generated once the PpIX is exposed to visible light (including 400–410 nm and 635 ± 5 nm) [<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover, 5-ALA-based PDT should be administered every 2–3 weeks, and repeated treatment is usually required to achieve desired results. Significantly, the treated areas should be strictly protected from light for 48 h after PDT, and this exposure prophylaxis would continue throughout the entire treatment. Once inadvertently exposed to sunlight or even indoor light, papules, macules, blisters, or erosion may occur in the PDT-treated areas [<xref ref-type="bibr" rid="CR14">14</xref>]. In addition, after the treatment, the lesions need to be protected from saliva for more than 3 h with thick gauze, which would restrict the patients' movement to a great extent [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. According to the literature, the recurrence rate of 5-ALA-based PDT is as high as 60% [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Therefore, more efficient and fewer side effect photosensitizers should be developed to better study the PDT treated OLK.</p><p id="Par43">The increasing cross-research between biomedicine and nanoscience provides more opportunities to develop new photosensitive materials for clinical treatment [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Near-infrared (NIR) phototherapy has been widely applied for biomedicine due to its deep tissue penetration, robust anti-tumor efficacy, lower drug resistance, high specificity, and minimal invasiveness [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In particular, photothermal therapy (PTT) is the other phototherapeutic method, which refers to light radiation and systemic local spot hyperthermia to heat the disaffected cells locally [<xref ref-type="bibr" rid="CR23">23</xref>]. PTT can cause protein denaturation and cell membrane rupture, leading to irreversible damage to the target lesions [<xref ref-type="bibr" rid="CR23">23</xref>–<xref ref-type="bibr" rid="CR25">25</xref>]. To conquer the limitations of 5-ALA-based PDT, integrating PDT/PTT into OLK can block the cancerization process, promote the extinction of OLK lesions, and truly achieve precision medicine.</p><p id="Par44">Herein, a novel acceptor–donor-acceptor (A-D-A) organic photosensitive nano-agents based on 3,9-bis(2-methylene-(3-(1,1-dicyanomethylene)-indanone))-5,5,11,11-tetrakis-(5-hexylthienyl) dithieno[2,3-d:2’,3’-d’]-s-indaceno[1,2-b:5,6-b’]dithiophene (ITIC-Th) is designed for PDT/PTT. ITIC-Th is an efficient fused-ring electron acceptor with an alkyl thiophene group chain, making excellent NIR absorption and emission [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]<sub>.</sub> By nanoprecipitation, we successfully prepared ITIC-Th nanoparticles (NPs) with a J-aggregative state, which present the advantages of redshift absorption, water solution, nontoxicity, and biodegradation ability. ITIC-Th NPs possess high photothermal conversion efficiency (~ 38%) and high ROS generation ability, endowing them with phototherapy both in vitro and in vivo. After studying the optical properties in vitro, we proved the local and system biosafety and excellent phototherapeutic efficacy. Furthermore, we successfully established a dynamic precancerous animal model similar to humans in pathogenesis, pathological changes, host immune activity, and molecular level. The in vivo study demonstrated that the malignant transformation could be effectively blocked through phototherapy. In this study, the multifunctional organic nano-agents were applied in the PDT/PTT treatment of OLK for the first time, and the established treatment mode was much close to the real clinical practice, which has a broad application prospect in treating oral precancerous lesions.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Materials</title><p id="Par45">ITIC-Th was purchased from Derthon (Shenzhen, China). Tetrahydrofuran (THF) and dichloromethane were purchased from Admas-Beta (Shanghai, China). DSPE-mPEG 2000 was purchased from ToYongBio Tech (Shanghai, China). Leuk-1 was kindly provided by Professor Li Mao of the University of Maryland Dental School (Baltimore, USA). CAL 27 and HaCaT cell lines were get from the American Type Culture Collection (ATCC; Manassas, VA, USA). Singlet Oxygen Sensor Green (SOSG) kit was from Invitrogen (Thermo Fisher Scientific, USA). 1, 3-diphenylisobenzofuran (DPBF) and 4-nitroquinoline 1-oxide (4NQO) were purchased from Sigma-Aldrich (Saint Louis, USA). Cell Counting Kit-8 (CCK-8) was purchased from Bimake (Shanghai, China). ROS assay kit and DAPI were obtained from Beyotime (Shanghai, China). Cyclin D1 Monoclonal Antibody, p53 Monoclonal Antibody, Aldehyde dehydrogenase isoform 1 (ALDH1) Polyclonal Antibody, Programmed cell death 5 (PDCD5) Polyclonal antibody, and β-Actin Monoclonal Antibody were purchased from Proteintech (Wuhan, China). The anti-podoplanin (PDPN) antibody was purchased from Abcam (Shanghai, China). 5-ALA was purchased from FUDAN-ZHANGJIANG (Shanghai, China). Paraformaldehyde was from BOSTER (Wuhan, China). The Super -maxvision mouse/rabbit universal HRP Kit was from Typing Biotech (Nanjing, China).</p></sec><sec id="Sec4"><title>Synthesis of ITIC-Th NPs</title><p id="Par46">Referring to the previous literature, ITIC-Th NPs were synthesized by the reprecipitation method [<xref ref-type="bibr" rid="CR28">28</xref>]. Briefly, under ultrasonic oscillation, 2 mL of ITIC-Th solution (250 μg/mL, THF) was dripped into the vigorously stirred DSPE-mPEG 2000 solution (1 mg/mL, ddH<sub>2</sub>O) slowly (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). After the solution was clear and transparent, THF organic solvent was removed and purified by rotary evaporation to obtain water-soluble ITIC-Th NPs.<fig id="Fig1"><label>Fig. 1</label><caption xml:lang="en"><p>The illustration of the synthesis of ITIC-Th NPs</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1310_Fig1_HTML.png" id="MO2"/></fig></p></sec><sec id="Sec5"><title>Characterization of ITIC-Th NPs</title><p id="Par47">The ITIC-Th NPs morphology was observed on a transmission electron microscope (TEM, Hitachi H-7600, Japan), and the hydrodynamic diameter was measured by a dynamic light scattering system (DLS, BT-90). The UV − vis spectrum was obtained by an UV − vis − NIR spectrophotometer (PerkinElmer LAMBDA 750), and the fluorescence spectrum was acquired by a photoluminescence spectrometer (FLS980, Edinburgh Instruments, UK). A NIR fluorescence camera detected the NIR fluorescence imaging. Different thickness beef covered NPs solutions were used to check the fluorescence penetration of NPs.</p></sec><sec id="Sec6"><title>Photothermal performance of ITIC-Th NPs</title><p id="Par48">The photothermal performance of ITIC-Th NPs solution was measured through recording the solution (0, 6.5, 12.5, 25.0, and 50.0 μg/mL) temperature change with 660 nm laser irradiation (0.4, 0.6, 0.8, 1.0, and 1.2 W/cm<sup>2</sup>) by an IR-thermal camera (FLIR, Arlington, VA, E50), while PBS was used as control. The photothermal conversion efficiency (η) of ITIC-Th NPs was calculated by the Formula (<xref rid="Equ1" ref-type="disp-formula">1</xref>) [<xref ref-type="bibr" rid="CR29">29</xref>]<disp-formula id="Equ1"><label>1</label><alternatives><mml:math display="block" id="Equ1_Math"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>η</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>h</mml:mi><mml:mi>A</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mi>T</mml:mi><mml:mi>M</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>S</mml:mi></mml:msub></mml:mfenced><mml:mo>-</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">Dis</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>A</mml:mi><mml:mn>660</mml:mn></mml:mrow></mml:msup></mml:mfenced></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><tex-math id="Equ1_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{array}{c}\eta =\frac{hA\left({T}_{M}-{T}_{S}\right)-{Q}_{Dis}}{I\left(1-{10}^{-A660}\right)}\end{array}$$\end{document}</tex-math><graphic specific-use="web" mime-subtype="GIF" xlink:href="12951_2022_1310_Article_Equ1.gif"/></alternatives></disp-formula>
where <italic>h</italic> is the heat transfer coefficient, A represents the container surface area, T<sub>M</sub> is the maximum temperature, T<sub>S</sub> means the ambient temperature. Q<sub>Dis</sub> is the heat dissipation, the I is the incident laser power, and A660 is the absorbance of the sample at 660 nm. The <italic>h</italic>A can be calculated from Formula (<xref rid="Equ2" ref-type="disp-formula">2</xref>)<disp-formula id="Equ2"><label>2</label><alternatives><mml:math display="block" id="Equ2_Math"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>τ</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mi>D</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">hA</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><tex-math id="Equ2_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{array}{c}{\tau }_{s}=\frac{{m}_{D}{c}_{D}}{hA}\end{array}$$\end{document}</tex-math><graphic specific-use="web" mime-subtype="GIF" xlink:href="12951_2022_1310_Article_Equ2.gif"/></alternatives></disp-formula>
where τ<sub>s</sub> is the time constant for heat transfer of the system, calculated from Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S1; m<sub>D</sub> and c<sub>D</sub> are the mass and heat capacity, respectively, of the water. Q<sub>Dis</sub> represents the heat dissipation from the light absorbed by the water and the quartz sample cell, so Q<sub>Dis</sub> was calculated according to Formula (<xref rid="Equ3" ref-type="disp-formula">3</xref>)<disp-formula id="Equ3"><label>3</label><alternatives><mml:math display="block" id="Equ3_Math"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">Dis</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:mfenced close=")" open="("><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mfenced close=")" open="("><mml:mi>w</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi></mml:mfenced></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>S</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:msub><mml:mi>τ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mfenced close=")" open="("><mml:mi>w</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi></mml:mfenced></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><tex-math id="Equ3_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{array}{c}{Q}_{Dis}=\frac{{c}_{D}{c}_{D}\left({T}_{M\left(water\right)}-{T}_{S}\right)}{{\tau }_{s\left(water\right)}}\end{array}$$\end{document}</tex-math><graphic specific-use="web" mime-subtype="GIF" xlink:href="12951_2022_1310_Article_Equ3.gif"/></alternatives></disp-formula>
where T<sub>M (water)</sub> is the maximum water temperature under laser irradiation.</p></sec><sec id="Sec7"><title>Photodynamic performance of ITIC-Th NPs</title><p id="Par52">The fluorescent probe SOSG and DPBF measured the generation of <sup>1</sup>O<sub>2</sub>. ITIC-Th NPs (25 μg/mL, ddH<sub>2</sub>O) were mixed with SOSG solution and irradiated by a 660 nm laser (1.0 W/cm<sup>2</sup>) over 10 min. The fluorescence spectrum of oxidized SOSG (excitation/emission: 488/525 nm) was recorded by a UV vis NIR spectrophotometer every 10 s. ITIC-Th NPs (25 μg/mL, dichloromethane) and DPBF (2 μM) were dissolved into THF, then the solution was followed by irradiation (660 nm, 1.0 W/cm<sup>2</sup>), then immediately detected the UV–Vis absorption. The <sup>1</sup>O<sub>2</sub> quantum yield was evaluated by previous literature using Formula (<xref rid="Equ2" ref-type="disp-formula">2</xref>) [<xref ref-type="bibr" rid="CR28">28</xref>].<disp-formula id="Equa"><alternatives><mml:math display="block" id="Equa_Math"><mml:mrow><mml:mi>φ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>k</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>φ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="italic">ref</mml:mi></mml:mrow></mml:mfenced><mml:mfenced close="]" open="["><mml:mfrac><mml:mrow><mml:mi>k</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>k</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mfenced><mml:mfenced close="]" open="["><mml:mfrac><mml:mrow><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>k</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mfenced><mml:mfenced close="]" open="["><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>k</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mfenced></mml:mrow></mml:math><tex-math id="Equa_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\varphi (unkown) = \varphi \Delta \left( {ref} \right)\left[ {\frac{{k(unkown)}}{{k(ref)}}} \right]\left[ {\frac{{F(ref)}}{{F(unkown)}}} \right]\left[ {\frac{{PF(ref)}}{{PF(unkown)}}} \right]$$\end{document}</tex-math><graphic specific-use="web" mime-subtype="GIF" xlink:href="12951_2022_1310_Article_Equa.gif"/></alternatives></disp-formula>
where <inline-formula id="IEq1"><alternatives><mml:math id="IEq1_Math"><mml:mrow><mml:mi mathvariant="italic">unkown</mml:mi></mml:mrow></mml:math><tex-math id="IEq1_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$unkown$$\end{document}</tex-math><inline-graphic specific-use="web" mime-subtype="GIF" xlink:href="12951_2022_1310_Article_IEq1.gif"/></alternatives></inline-formula> and ref are the 'ITIC-Th NPs' and 'MB', respectively. Quantum yields of singlet oxygen measured upon irradiation at MB as reference took into account as 0.52. k is the slope of the difference in change in absorbance of DPBF with the irradiation time. F is the absorption correction factor given by F = 1–10<sup>−OD</sup> (OD at the irradiation wavelength), and PF is the laser power.</p></sec><sec id="Sec8"><title>Cell culture</title><p id="Par54">Leuk-1, a premalignant leukoplakia cell line, was cultured in a defined keratinocyte serum-free medium (K-SFM; GIBCO, Invitrogen, Grand Island, USA). The OSCC cell line CAL 27 and human immortalized keratinocyte line (HaCaT) were cultured in a complete Dulbecco's modified Eagle's medium (DMEM, Key GEN Bio TECH, China) medium with 10% Fetal Bovine Serum (FBS, BI, Israel). These cells were cultured in an incubator at 37 °C with 5% CO<sub>2</sub>.</p></sec><sec id="Sec9"><title>Cell cytotoxicity assay</title><p id="Par55">The CCK-8 assay detected the cytotoxicity of ITIC-Th NPs in Leuk-1 cells. Leuk-1 cells were seeded into a 96-well plate with different concentrations of ITIC-Th NPs and incubated for 24 h, then some of them were exposed to 660 nm laser (1.0 W/cm<sup>2</sup>) irradiation. Afterward, a CCK-8 assay was used to detect the cell viability of different groups. Another group of Leuk-1 cells was seeded in six-well plates and incubated overnight. The medium was replaced with fresh K-SFM containing ITIC-Th NPs or not. After another incubation for 12 h, cells were exposed to a 660 nm laser, and the cells were washed with PBS three times. Calcein-AM/PI Double Staining Kit labeled live cells in green and dead cells in red under the confocal microscope.</p></sec><sec id="Sec10"><title>Detection of intracellular ROS</title><p id="Par56">Intracellular ROS level was detected using the ROS Assay Kit. 1 × 10<sup>6</sup> Leuk-1 cells were planted into a 35 mm glass-bottomed dish overnight. The attachable cells were cocultured with ITIC-Th NPs for another 4 h, after washing with PBS, 2, 7-dichlorodi-hydrofluorescein diacetate (DCFH-DA) probe with the K-SFM medium at 1: 1000 was added to the dishes and incubated for 20 min, followed by 660 nm laser irradiation (1.0 W/cm<sup>2</sup>). Fluorescence was detected by the Nikon Digital Eclipse A1 Plus microscope.</p></sec><sec id="Sec11"><title>Western blot analysis</title><p id="Par57">Proteins were extracted from the HaCaT /CAL 27/Leuk-1 cell. The primary antibodies used were p53, PDPN, ALDH1, Cyclin D1, and PDCD5. β-actin was used as the loading control. Protein levels were quantified using Image-Pro Plus and normalized to the β-actin level by densitometry.</p></sec><sec id="Sec12"><title>Patients</title><p id="Par58">Ten patients undergoing surgical treatment for oral leukoplakia in the Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital (Jiangsu, China), from January 2018 to December 2019 were recruited to our study, half of them had epithelial dysplasia and the other half did not. Oral leukoplakia was clinically diagnosed and confirmed using histology. The specific clinical features are shown in Table S1. Informed consent was obtained from each patient. This study was approved by the Nanjing Stomatological Hospital Ethics Committee (Application Permit Number: 2019NL-029(KS)).</p></sec><sec id="Sec13"><title>Immunohistochemical staining and score</title><p id="Par59">Immunohistochemistry was carried out according to the manufacturer's protocols. All immunostained sections were independently assessed and scored by two experienced pathologists using Imagescope software (Scanscope, USA) for quantitative analysis of images based on the visual evaluation. The related protein was quantified by visual grading according to the degree of staining: 0 (&lt; 5%), 1 (6–25%), 2 (26–50%), 3 (51%-75%), 4 (&gt; 75%), staining strength: 0 (no staining), 1 (weak staining), 2 (medium staining), 3 (strong staining). The scores were multiplied according to the intensity and degree of staining to obtain the final immune response score.</p></sec><sec id="Sec14"><title>Establishment of oral leukoplakia model in rats</title><p id="Par60">A total of 28 female-specific pathogen-free Sprague–Dawley (SD) rats, six to eight weeks of age, were purchased from Beijing Vitalstar Biotechnology Co.,Ltd. All animal experiments were followed by the guidelines international and national approved by the Nanjing Stomatological Hospital Ethics Committee (Application Permit Number: 2019NL-029(KS)). After a week of acclimation, 26 rats were treated with 75 µg/ml 4NQO dissolved in propylene glycol in the drinking water, and the remaining two rats were treated with normal drinking water. One rat was sacrificed in the 8th and 12th weeks, respectively. The tongue was excised, cut longitudinally, and fixed with 10% buffer formaldehyde for 48 h. According to the manufacturer's protocols, the tissues were then paraffin-embedded, sectioned at 4 μm, and stained with hematoxylin and eosin (H&amp;E). In the 16<sup>th</sup> week, two 4NQO rats and two normal drinking rats were sacrificed to evaluate the progress of oral leukoplakia and the biosafety of 4NQO. The tongue, heart, liver, spleen, lung, and kidney were resected to perform histopathological analysis. The induction lasted for 16 weeks, with all rats drunk as needed and switched to purified water at week 17.</p></sec><sec id="Sec15"><title>Thermal imaging</title><p id="Par61">Finally, twenty rats with typical white patches on the back of the tongue were selected and randomly separated into five groups (n = 4 per group, blank control, PBS/ALA with laser irradiation, ITIC-Th NPs with or without laser irradiation). The remaining two rats were excluded because of atypical leukoplakia or inappropriate location. The rats were anesthetized by 2% isoflurane inhalation, after complete sedation, a mouth gag was applied to open their mouth and take out their tongues. The first group received no injections, while Group 2 was intralesional injection with 100 μl PBS, Group 3 with 100 μl freshly prepared 20% 5-ALA, and Group 4/5 with the same dose of 100 μg/ml ITIC-Th NPs. Injections made from the marginal base of the target area and the scope should exceed 3–5 mm beyond the edge of the intended treatment site. In Group 1/2/5, the thermal imaging was measured by an infrared camera (FLIR, C3) at different time points following a 660 nm laser (1 W/cm<sup>2</sup>) irradiation for 3 min. While in the third group, a 365 nm UV light was performed 3 h post-injection to test the illumination reaction. Afterward, a laser at the wavelength of 632 nm (0.5 W/cm<sup>2</sup>) was also irradiated for 3 min. Therapies were conducted every five days and each rat received three treatments.</p></sec><sec id="Sec16"><title>Efficacy evaluation in vivo</title><p id="Par62">The therapeutic effect was evaluated and independently scored by two experienced oral mucosal clinicians. Four parameters were assessed for each subject, including size, type, color, and texture [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. If the lesions extended to two or more sites, the site with more severe lesions was selected as the target area for evaluation. The size of the oral leukoplakia was determined by measuring any clinically visible area of morphological change and calculated as 'length × width'. The same investigator made measurements before the treatment (Day 0) and after complete treatment (Day 14), respectively. Before treatment, all initial areas were recorded as 0 points. On day 14, compared with the previous period, the cross-sectional area of measurable leukoplakia decreased by ≥ 50% was recorded as negative 2 points, increased by ≥ 50% was recorded as 2 points, and the rest of them were labeled as 0 points. The types of lesions are mainly divided into three grades according to surface roughness, protuberance degree, ulcer or erosion: granular protuberance, verrucous protuberance, villous protuberance or prickly protuberance, which are significantly higher than the mucosal surface, or those with ulcers are marked as 3 points; Uneven and higher than the mucosal surface, the local ulcer was marked as 2 points; Homogeneous plaques slightly above the mucosal surface without ulceration were scored as 1 point. Color is divided into two grades, pure white is marked as 2 points, gray or light white is marked as 1 point. The texture is graded on three scales, with 3 for hard, 2 for medium, and 1 for soft. The total score was calculated by adding up all the scores. Cases that are clinically evaluated as cancerous are scored directly as 10 points. All operations were performed under anesthesia. Finally, all of the rats were euthanized on the 14th day, tongues were collected, and stained by H&amp;E. Immunohistochemistry (ALDH1 and p53) was carried out according to the manufacturer's protocols.</p></sec><sec id="Sec17"><title>Chronic toxicity experiment</title><p id="Par63">The body weight was measured and recorded every 2 days. After rats were sacrificed, the tongues and their adjacent tissues, the major organs were gathered for histological analysis, and blood samples were collected for routine and biochemical examinations.</p></sec><sec id="Sec18"><title>Statistical analysis</title><p id="Par64">All analyses were carried out as indicated by GraphPad Prism 8.0. Mean and standard deviation was used as descriptive statistics. The student's <italic>t</italic>-test was used to calculate statistical differences between two groups, and one-way analysis of variance (ANOVA) was used to compare differences between more than two groups. The value of p &lt; 0.05 was considered statistically significant.</p></sec></sec><sec id="Sec19"><title>Results and discussion</title><sec id="Sec20"><title>Preparation and characterization</title><p id="Par65">ITIC-Th NPs were synthesized by the nanoprecipitation method reported in our previous literature [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR32">32</xref>] and had a uniform and transparent appearance in an aqueous solution (Fig. <xref rid="Fig2" ref-type="fig">2</xref>A). TEM images of ITIC-Th NPs presented a diameter of approximately 50 nm with spherical-like morphology (Fig. <xref rid="Fig2" ref-type="fig">2</xref>B), in diameter in favor of cellular uptake [<xref ref-type="bibr" rid="CR33">33</xref>]. DLS results indicated that the average size of ITIC-Th NPs was nearly 60 nm, which was consistent with the TEM result (Fig. <xref rid="Fig2" ref-type="fig">2</xref>C). The element mapping analysis also showed the corresponding element distribution in the NPs (Fig. <xref rid="Fig2" ref-type="fig">2</xref>D), where the carbon (C), nitrogen (N), sulfur (S), and oxygen (O) were marked as red, cyan, blue, and green, respectively, indicating the success of synthesizing. The UV–Vis spectrum of free ITIC-Th exhibited peaks at 646 nm. When ITIC-Th NPs were formed, the peak showed a redshift to 692 nm, which confirmed the presence of NPs (Fig. <xref rid="Fig2" ref-type="fig">2</xref>E). The fluorescence spectra of ITIC-Th NPs showed that the emission peak was 820 nm (Fig. <xref rid="Fig2" ref-type="fig">2</xref>F), indicating the fluorescence imaging ability in the near-infrared [<xref ref-type="bibr" rid="CR34">34</xref>]. To test the stability of NPs, we checked the particles' size and appearance in different solutions for two weeks [<xref ref-type="bibr" rid="CR35">35</xref>]. The results showed that the as-prepared NPs had good stability (Fig. <xref rid="Fig2" ref-type="fig">2</xref>G and Fig S1A). Considering the microenvironment in OLK, we further checked the stability of NPs under different pH circumstances. The UV–VIS spectrum and DLS results showed a minimal difference between different pH, indicating that the property of NPs can stay stable regardless of the environment (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S1B, C). All those data suggested that the NPs were stable enough for therapy in vitro and in vivo.<fig id="Fig2"><label>Fig. 2</label><caption xml:lang="en"><p>The characterization of ITIC-Th NPs. <bold>A</bold> Optical image of the ITIC-Th NPs water solution in a cuvette. <bold>B</bold> The TEM image of ITIC-Th NPs in water solution. Scale bar = 100 nm. <bold>C</bold> The DLS profiles of ITIC-Th NPs in water (10 μg/mL). The average diameters of ITIC-Th NPs were approximately 60 nm, consistent with the TEM result. <bold>D</bold> The corresponding energy-dispersive spectroscopy (EDS) results of ITIC-Th NPs (The corresponding elements were marked in different colors in the image). <bold>E</bold> UV absorbance spectrum of ITIC-Th and ITIC-Th NPs (20 μg/mL) solution. <bold>F</bold> The fluorescence emission spectrum of ITIC-Th and ITIC-Th NPs under emission of 660 nm. <bold>G</bold> The average diameter of ITIC-Th NPs in corresponding solutions (water, PBS, DMEM, and FBS) after 2 weeks. <bold>H</bold> Photothermal profiles of ITIC-Th NPs in PBS under different power density irradiation (660 nm, 0.4, 0.6,0.8,1.0, and 1.2 W/cm<sup>2</sup>). <bold>I</bold> Photothermal profiles of ITIC-Th NPs in PBS with different concentrations (6.25, 12.5, 25.0, and 50.0 μg/mL) under laser irradiation (660 nm, 1 W/cm<sup>2</sup>). <bold>J</bold> The heating curve of the ITIC-Th NPs in PBS during 5 cycles of on-and-off laser irradiation (660 nm, 1 W/cm<sup>2</sup>). <bold>K</bold> Fluorescence spectra of ITIC-Th (20 μg/mL) mixed with SOSG (10<sup>–5</sup> mol/L) upon laser irradiation (660 nm, 1 W/cm<sup>2</sup>) with various duration. <bold>L</bold> Fluorescence intensity was measured at different time intervals. <bold>M</bold> Absorption spectra of ITIC-Th (20 μg/mL) mixed with DPBF (6 × 10<sup>−5</sup> mol/L) under laser irradiation (660 nm, 1 W/cm<sup>2</sup>) with various durations</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1310_Fig2_HTML.png" id="MO3"/></fig></p></sec><sec id="Sec21"><title>Photothermal and photodynamic properties</title><p id="Par66">The photothermal properties of the ITIC-Th NPs were evaluated by using a 660 nm laser as the excitation light. The photothermal effect of ITIC-Th NPs was positively correlated with the power density. The elevated temperature of ITIC-Th NPs (100 μg/mL) gradually increased from 11.1 °C to 34.9 °C at 10 min' irradiation (the power density from 0.4 to 1.2 W/cm<sup>2</sup>). Even at a low intensity of 0.8 W/cm<sup>2</sup>, the solution temperature was still lifted by 24.7 °C (Fig. <xref rid="Fig2" ref-type="fig">2</xref>H). The temperature variation curves of ITIC-Th NPs solutions were also positively correlated with concentration. Under continuous laser irradiation (1.0 W/cm<sup>2</sup>), the temperature of ITIC-Th NPs (50 μg/mL) could increase by 26.5 °C at 10 min, which demonstrated the excellent photothermal performance (F<xref rid="Fig2" ref-type="fig">i</xref>g. <xref rid="Fig2" ref-type="fig">2</xref>I). The photothermal conversion efficiency (η) [<xref ref-type="bibr" rid="CR29">29</xref>] of ITIC-Th NPs was calculated to be nearly 38.6% (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S2A, B). Subsequently, we further examined the photothermal stability of ITIC-Th NPs, which is vital towards a photosensor [<xref ref-type="bibr" rid="CR36">36</xref>]. We found that the maximum photothermal temperature of ITIC-Th NPs barely changed after five reversible heating and cooling cycles (Fig. <xref rid="Fig2" ref-type="fig">2</xref>J). This result highlighted the excellent photothermal stability of ITIC-Th NPs, which was beneficial for PTT application in vivo<italic>.</italic> To determine the singlet oxygen (<sup>1</sup>O<sub>2</sub>) production of ITIC-Th NPs, the fluorescent probe SOSG and DPBF were utilized, respectively. The intensity of ITIC-Th NPs and SOSG solution drastically increased under laser irradiation at 525 nm (660 nm, 1.0 W/cm<sup>2</sup>), indicating the amount of singlet oxygen generation. The singlet oxygen production of ITIC-Th NPs was 6.82% (Fig. <xref rid="Fig2" ref-type="fig">2</xref>K and L), which is close to that of free ICG (7.7%) used in the clinic [<xref ref-type="bibr" rid="CR37">37</xref>]. The ROS generation ability of ITIC-Th NPs was further measured by using DPBF as a probe [<xref ref-type="bibr" rid="CR38">38</xref>]. Figure <xref rid="Fig2" ref-type="fig">2</xref>M indicated the excellent ROS generation ability of ITIC-Th NPs. An electron spin resonance (ESR) test was conducted to analyze ROS species, which showed that the superoxide radical is the major radical oxygen species (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S2C). The research results mentioned above demonstrated superior photothermal and photodynamic properties. During the treatment, the PDT-inducing cell dying can lead to the related antigen releasing. The PTT can increase local blood flow, promoting tissue healing and immune-related cells in vivo. Also, the cellular excessive ROS level could induce oxidative modification in other oxygen species, proteins, or lipids, even resulting in cellular damage and cell death [<xref ref-type="bibr" rid="CR39">39</xref>], resulting in the relative cell markers alter.</p></sec><sec id="Sec22"><title>In vitro cytotoxicity</title><p id="Par67">The NIR imaging was used to determine the fluorescence imaging ability of ITIC-Th NPs. In vitro fluorescence imaging showed that pure PBS had no imaging capability, and the signal was generated with the addition of ITIC-Th NPs (Fig. <xref rid="Fig3" ref-type="fig">3</xref>A). Moreover, the fluorescence intensity increased with the increasing concentration and presented the brightest signal when the concentration reached 75 μg/mL compared to the background, proving that the ITIC-Th NPs had good imaging capability (Fig. <xref rid="Fig3" ref-type="fig">3</xref>B). Encouraged by the excellent fluorescence imaging property, we further tested the penetration ability of ITIC-Th NPs solution in NIR. Fluorescence imaging was used to detect penetration by covering different beef over the NPs solution. Even when the tissue thickness was increased to 4 mm, the NIR imaging can clearly show the contour of the capillary, suggesting the excellent tissue penetration of NPs (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S3). The cytotoxicity of ITIC-Th NPs towards Leuk-1 cells in vitro was confirmed by CCK-8 assays in the presence or absence of 660 nm laser irradiation. Interestingly, ITIC-Th NPs were non-toxic to human keratinocytes HaCat and other normal cell lines (RAW 264.7 and THP-1) (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S4A–C). Still, in premalignant leukoplakia cells, cell viability was suppressed dramatically under laser contrast to the no laser illumination group (Fig. <xref rid="Fig3" ref-type="fig">3</xref>C). IC<sub>50</sub> values were calculated using GraphPad Prism 8.0, compared with hematoporphyrin (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S4D), ITIC-Th NPs (IC<sub>50</sub> = 10.36 μg/mL) showing a more apparent inhibitory effect on cell activity, implying the highly desirable PDT/PTT effect of ITIC-Th NPs, which was an effective method to avoid the potential drug side effects. Accordingly, 10 μg/mL was selected as the working concentration for subsequent experiments. To better analyze the cellular uptake of NPs, we used fluorescent PEG to visualize the particles in cells. The fluorescence showed the particles could distribute in the cells along the time (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S5). The mechanism of cell death was further analyzed by FITC-Annexin V/ propidium iodide staining. ITIC-Th NPs were cultured in Leuk-1 cells at the concentration of 10 μg/mL with or without laser illumination (660 nm, 1 W/cm<sup>2</sup>), and non-treated cells were taken as control. The results observed by confocal laser microscopy were shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>D. Live cells were stained with Calcein-AM to show a green fluorescence signal, while dead cells were stained with PI to show red fluorescence signal. The cells were green in control, NPs, hematoporphyrin (Hem), laser group, meaning that the cells were sound and the NPs were safe without laser irradiation. After laser illumination, the ratio of cells with red signal was increased dramatically in the NPs group, suggesting the effective killing rate compared with the Hem group. The quantitative analysis was demonstrated in Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S6A, which consists of fluorescent images. All these data showed that the NPs possessed excellent biocompatibility without laser application but had a better therapeutic effect under laser irradiation than hematoporphyrin.<fig id="Fig3"><label>Fig. 3</label><caption xml:lang="en"><p>In vitro therapeutic evaluation of ITIC-Th NPs. <bold>A</bold> Fluorescence images of ITIC-Th NPs with a different concentration in PBS (Excitation wavelength: 660 nm). <bold>B</bold> Relationship between concentration of ITIC-Th and NIR fluorescence intensity. <bold>C</bold> CCK-8 evaluated the cell cytotoxicity assay. Leuk-1 cells were treated with various formulations for 24 h. <bold>D</bold> The fluorescence of Live/Dead cells. Live and dead cells were signaled in green and red fluorescence, respectively. Scale bar = 100 μm. <bold>E</bold> Fluorescence photographs of cellular ROS generation treated with ITIC-Th NPs (10 μg/mL). Scale bar = 100 μm. <bold>F</bold> Representative immunoblots indicated different protein levels in CAL 27 from each treatment group, and the quantitative analysis was shown in G. <bold>H</bold> Representative immunoblots indicated different protein levels in Leuk-1 from each treatment group, and the quantitative analysis was shown in I (**p &lt; 0.01; ***p &lt; 0.001)</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1310_Fig3_HTML.png" id="MO4"/></fig></p></sec><sec id="Sec23"><title>ITIC-Th NPs inhibited OLK carcinogenesis in vitro</title><p id="Par68">The generation of ROS plays a crucial role in treating OLK with PDT. Based on the efficient ROS generation ability in solution, we used the 2ʹ,7ʹ-dichlorofuorescin diacetate (DCFH-DA) probe to test the intracellular ROS generation in different groups and analyzed by CLSM and Image J [<xref ref-type="bibr" rid="CR40">40</xref>]. DCFH-DA has no fluorescence, but it can be rapidly converted into fluorescent 20, 70-dichlorofluorescein by ROS [<xref ref-type="bibr" rid="CR41">41</xref>]. As shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>E, a strong green fluorescence could be observed in Leuk-1 cells incubated with ITIC-Th NPs after laser irradiation (660 nm, 1 W/cm<sup>2</sup>). In contrast, negligible hematoporphyrin was emitted without ITIC-Th NPs or laser, suggesting the NPs produced much ROS after laser irradiation [<xref ref-type="bibr" rid="CR42">42</xref>]. Furthermore, taking the hematoporphyrin with laser as a compared group, the green fluorescence is much more than that, indicating the effective ROS generation. The quantitative result in Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S6B further supported this conclusion (P &lt; 0.01). These results proved that ITIC-Th NPs promoted a remarkable PDT therapeutic effect.</p><p id="Par69">As high intracellular ROS levels can induce cell damage and even death, we speculate this may change the relative markers. To date, some biological biomarkers have been reported of potential value in predicting malignant transformation of oral leukoplakia, such as ALDH1, p53, Cyclin D1, PDCD5, and PDPN [<xref ref-type="bibr" rid="CR43">43</xref>–<xref ref-type="bibr" rid="CR45">45</xref>]. ALDH1, an isomer of aldehyde dehydrogenase, has been demonstrated to be a tumor stem cell marker for various solid tumors, including OSCC, and can be used as a prognostic marker for head and neck squamous cell carcinoma (HNSCC) survival [<xref ref-type="bibr" rid="CR46">46</xref>]. p53 was known as a tumor suppressor gene that induced cell apoptosis, necrosis, and autophagy under cell stress. The mutation and inactivation of p53 were crucial in developing OLK [<xref ref-type="bibr" rid="CR47">47</xref>]. Cyclin D1, a regulator of Cyclin-dependent kinase (CDK), promotes cell cycle progression during the G1 phase, which played a key role in cell proliferation and growth regulation, mitochondrial activity modulation, DNA repair, and cell proliferation migration control [<xref ref-type="bibr" rid="CR48">48</xref>]. PDCD5 can be involved in programmed cell death, cell cycle, embryonic development, and immune regulation. The expression rate of PDCD5 deletion was consistent with the positive expression rate of mutant p53 and was decreased in laryngeal squamous cell carcinoma but still unclear in OSCC [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. PDPN was a mucin-type transmembrane glycoprotein, and positive expression of ALDH1/p53/Cyclin D1/PDPN was significantly associated with malignant transformation of OLK [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. As shown in F<xref rid="Fig3" ref-type="fig">i</xref>g. <xref rid="Fig3" ref-type="fig">3</xref>F–I, the ALDH1/p53/ Cyclin D1/PDPN/PDCD5 protein expression levels significantly decreased after co-cultured with ITIC-Th NPs and laser irradiation (660 nm, 1 W/cm<sup>2</sup>). In particular, this phenomenon was more outstanding in the human tongue cancer cells than in the leukoplakia cells. These results indicated that ITIC-Th NPs could significantly down-regulate the expression of tumor-related genes in vitro. Since these biomarkers were associated with the risk of OLK's malignant transformation, we speculated that with photothermal and photodynamic effects, ITIC-Th NPs may prevent oral precancerous lesions from transforming into OSCC, although the specific mechanism still needs further studies.</p><p id="Par70">To further determine the meaning of relative protein in oral leukoplakia, we detected the expression levels of these biomarkers in oral leukoplakia tissues with different levels of epithelial dysplasia. A total of 10 OLK patients (3 males and 7 females, mean age 59.6 ± 14.1 years) were enrolled in the study. Five of them had epithelial dysplasia, and the remaining did not. Compared with simple hyperplastic tissues, the ALDH1/p53/Cyclin D1/PDPN protein expression was more obvious in the tissues with epithelial dysplasia, which was significantly associated with malignant transformation of OLK. The role of PDCD5 in the development of OLK remains to be elucidated. In our research, PDCD5 expression was decreased with increasing histological grade, which was consistent with ovarian epithelial cancer findings, suggesting that it may also play an important role in OLK carcinogenesis (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S7).</p></sec><sec id="Sec24"><title>Successful establishment of the oral leukoplakia rat model</title><p id="Par71">4NQO is an aromatic amine heterocyclic compound widely used as the most recognized chemical precursor carcinogen [<xref ref-type="bibr" rid="CR14">14</xref>]. Research has certified that 4NQO establishes precancerous or cancerous models by causing intracellular oxidative stress, DNA adduction, mutagenesis, and tumor induction [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. 4NQO-induced precancerous model is a multi-stage dynamic and continuous process from normal oral mucosa to OLK until OSCC, and pathological stages underwent hyperplasia, dysplasia (mild, moderate, and severe), carcinoma in situ, and invasive SCC [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. This model closely mimics the carcinogenesis of human oral dysplasia that is suitable for studying the specific cancerous process of OLK, especially in the development of biomarkers for early diagnosis and epithelial cell transformation [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. After feeding at 75 µg/ml 4NQO drinking water, all rats were anesthetized by isoflurane inhalation at 8, 12, and 16 weeks [<xref ref-type="bibr" rid="CR58">58</xref>]. Researchers pulled outward the tongues to observe the changes, the typical tissue was chosen for histopathological examination. In the 8th week, the tongues remained normal, while in the 12th week they started to turn white. From this point on, all of the rats gradually exhibited non-detachable white plaque, and typical lesions appeared at week 16 similar to human oral leukoplakia (Fig. <xref rid="Fig4" ref-type="fig">4</xref>A). 4NQO has been proved to induce cancer in many parts of the oral cavity, such as the dorsal tongue, ventral tongue, palate, and even esophagus [<xref ref-type="bibr" rid="CR53">53</xref>]. Many studies have confirmed that tongue lesions occurred almost 100%, especially on the dorsal mucosa. In our study, lesions localized mainly on the tongue dorsum with a few lesions on the palate or along the lateral borders of the tongue, which was consistent with the previous reports [<xref ref-type="bibr" rid="CR53">53</xref>]. In the 16th week, we picked two 4NQO-treated rats at random and found varying degrees of pathological changes in tongue lesions, including simple oral leukoplakia and oral leukoplakia with mild, mild-to-moderate, or severe epithelial dysplasia (Fig. <xref rid="Fig4" ref-type="fig">4</xref>B). Also, the two normal drinking rats were sacrificed. Figure <xref rid="Fig4" ref-type="fig">4</xref>C showed no significant difference in histopathological features of major organs between 4NQO-treated and healthy rats. All the results above indicated that we had successfully established the rat model of oral leukoplakia, and 4NQO did not cause significant damage to the main organs in rats, and the rats can be used for further in vivo experiments.<fig id="Fig4"><label>Fig. 4</label><caption xml:lang="en"><p>Induction of oral dysplastic lesions. <bold>A</bold> Representative images of isolated tongues at different administration time points. <bold>B</bold> Representative images of H&amp;E staining of tongue tissue specimens of SD rats at week 16, including <bold>a</bold> Simple oral leukoplakia, <bold>b</bold> Oral leukoplakia with mild dysplasia, <bold>c</bold> Oral leukoplakia with mild-to-moderate dysplasia, <bold>d</bold> Oral leukoplakia with severe dysplasia (Scale bar = 200 μm). <bold>C</bold> H&amp;E-stained histological images of major organs were collected after 16 weeks with/without 4NQO treatment (Scale bar = 200 μm). <bold>D</bold> In vivo infrared thermal images of rats under laser irradiation at different time intervals after intralesional injection with PBS/ALA/ITIC-Th NPs. Circles indicate the oral leukoplakia area at the base of the tongue. <bold>E</bold> The tongue's temperature evolution was measured in (<bold>D</bold>). (n = 4, mean ± SD)</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1310_Fig4_HTML.png" id="MO5"/></fig></p></sec><sec id="Sec25"><title>In vivo PTT/PDT of ITIC-Th NPs against oral leukoplakia</title><p id="Par72">To explore the therapeutic effect of ITIC-Th NPs on oral leukoplakia in vivo and compared with the previous photosensitizer, we selected twenty rats with typical white plaque lesions on the dorsal surface of the tongue and randomly divided them into five groups (n = 4) for PTT/PDT. The rats received intralesional injections of 100 μg/ml ITIC-Th NPs or 20% 5-ALA and were irradiated with/without 660/632 nm laser for 3 min [<xref ref-type="bibr" rid="CR14">14</xref>]. In clinical practice, doctors often choose gauzes soaked with the photosensitizer solution to reduce needle insertion pain to place over the lesion, and patients should minimize oral activity. Since we could not keep the rats' tongues inactive for three hours, the intralesional injection was applied to reduce the influence of salivary secretion or tongue movement on ALA absorption. The schedule was shown in Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig S8. Rats without drug injections were used as blank controls, and rats injected with PBS were used as negative controls. The efficient accumulation of particles in pathological tissues is the key to PDT/PTT therapy. As the treatment schematic illustration is shown in Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Fig. S8, local injection ensures direct access of NPs to the diseased tissue and local accumulation of solution after injection. A thermal monitor was used to observe the photothermal capacity of ITIC-Th NPs in vivo at different time points. The lesions' temperature of ITIC-Th NPs + laser group rapidly increased and reached about 48.1 °C, suggesting the superior photothermal conversion of such ITIC-Th NPs. Pure ITIC-Th NPs did not heat up in the absence of light, and ALA had a photodynamic effect but no photothermal effect, so the temperature of the other four groups had hardly changed (Fig. <xref rid="Fig4" ref-type="fig">4</xref>D, E). The NPs can work with PDT and PTT, which owe better therapeutic effects than ALA.</p><p id="Par73">All operations above were performed by the same operator, conducted every five days and each rat received three treatments. After treatment, clinical, histological, and biological indicators were assessed. During the next 14 days, changes in tongue lesions were monitored and recorded. Two experienced oral mucosal clinicians evaluated the therapeutic effect independently, and the particular method was described above. None of our cases had achieved complete clinical response (CR, mean disappearance of all measurable disease). We speculated this was due to the continuous accumulation of 4NQO in the body [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. The dysplasia continued to worsen even though the 4NQO drinking water was switched back to purified water. This phenomenon could be verified in the blank control group (Table S2). The negative controls showed a faster oral leukoplakia cancerization rate, proving that only laser irradiation had no therapeutic effect. Otherwise, pure injection of ITIC-Th NPs showed limited cancerization inhibition, indicating a poor therapeutic effect of the NPs alone. According to meta-analysis, ALA-PDT's overall response rate (including complete and partial response) to OLK was estimated at 76.1% [<xref ref-type="bibr" rid="CR10">10</xref>]. In our study, the therapeutic effect of ALA-PDT was slightly better than that of the control group. In contrast, for the ITIC-Th NPs group with 660 nm laser irradiation, the progression of carcinogenesis was almost controlled, and in several cases, the degree of keratosis was reversed due to the combined PTT and PDT effects, which showed high inhibition efficiency compared to ALA-PDT only (Fig. <xref rid="Fig5" ref-type="fig">5</xref>A and C). Furthermore, the immunohistochemical studies of tongue oral leukoplakia sections also highly supported the anti-carcinogenesis effects of various treatments, consistent with in vitro studies (Fig. <xref rid="Fig5" ref-type="fig">5</xref>B and <xref rid="Fig5" ref-type="fig">D</xref>). The highest expression of ALDH1 and p53 was observed in the control group. In contrast, after being treated with ITIC-Th NPs + 660 nm laser, ALDH1 and p53 expression were significantly down-regulated. Therefore, the ITIC-Th NPs held superior anti-carcinogenesis efficacy.<fig id="Fig5"><label>Fig. 5</label><caption xml:lang="en"><p>ITIC-Th NPs therapy intercepts the cancerous progression of oral leukoplakia in 4NQO rats. <bold>A</bold> Manifestations of tongue lesions in rats on days 3, 8, and 14 after different treatments. <bold>B</bold> Representative histological images of H&amp;E, ALDH1, and p53 staining of collected tongue tissues. Scale bar = 200 μm. <bold>C</bold> Therapeutic effect scores of each group. According to lesion area, type, color, and texture, comprehensive judgment was made by two experienced oral mucosal clinicians. (n = 4, mean ± SD). <bold>D</bold> The score of ALDH1 and p53 IHC stain in B. (n = 4, mean ± SD, *p &lt; 0.05, ***p &lt; 0.001). <bold>E</bold> H&amp;E-stained histological images of major tissues near the site of treatments. Scale bar = 200 μm. <bold>F</bold> Average body weight of different groups of rats. (n = 4, mean ± SD). <bold>G</bold> H&amp;E-stained histological images of major organs after the different treatments. Scale bar = 200 μm. <bold>H</bold>–<bold>M</bold> Serum biochemical study and hematology assay after the different treatments. (n = 4, mean ± SD)</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1310_Fig5_HTML.png" id="MO6"/></fig></p><p id="Par74">In addition to the medical effectiveness of phototherapy, the long-term safety of photosensitizer must be considered. The biotoxicity of drugs was crucial for future biomedical application, so we conducted the biocompatibility of ITIC-Th NPs with SD rats. There was no apparent damage to the nearby vital tissues (upper lip, low lip, mucosa, sublingual gland, submaxillary lymph node (LN), and cervical LN, Fig. <xref rid="Fig5" ref-type="fig">5</xref>E), indicating the excellent biosafety of NPs. After intralesional injection of ITIC-Th NPs and laser irradiation, the body weight was recorded every other day. Each group did not have meaningful weight changes during the treatment (Fig. <xref rid="Fig5" ref-type="fig">5</xref>F). Major organs (heart, liver, spleen, lung, and kidney) were collected for H&amp;E staining, and no noticeable pathological changes were observed (Fig. <xref rid="Fig5" ref-type="fig">5</xref>G). Blood samples were obtained from the eyes of SD rats. The results of blood routine, liver function, and kidney function indexes showed no differences among the groups, suggesting the safety of this therapy (Fig. <xref rid="Fig5" ref-type="fig">5</xref>H–M). Given all the evidence above, the ITIC-Th NPs had superior biosafety and displayed an extraordinary capability against oral leukoplakia carcinogenesis.</p><p id="Par75">To prevent the progression of the OPMDs to OSCC is critical to the treatment of OSCC. Local drug therapy, PDT, and surgical excision were the typical clinical therapy in the clinic, depending on different stages of OPMDs progression [<xref ref-type="bibr" rid="CR14">14</xref>]. Local drug therapy with uncertain effects and an extended period, and the surgery is an invasive operation and full of terror to patients. The ALA-based PDT towards OLK owed the disadvantage of low response rate and complex process before and after the practice, which bring non-ideal therapeutic effect and uncomfortable feeling [<xref ref-type="bibr" rid="CR15">15</xref>]. To conquer the practical problems, our NPs with nanoscale can work with both PDT and PTT after laser illumination via local injection, which can shorten the course of treatment and reduce painfulness if injection with anesthetics. Also, compared with ALA, the NPs can easily enter cells and further influence cell metabolism [<xref ref-type="bibr" rid="CR61">61</xref>]. Our study showed that the tumor-relative markers were altered to a normal stage in vitro and in vivo, which ultimately induced apoptosis of OLK cells and hindered malignant transformation progression. Huge amounts of research prove that the PTT-induced cells damage can release the damage-associated molecular patterns (DAMP) [<xref ref-type="bibr" rid="CR62">62</xref>], which can initiate the immune response in tumor therapy. Though immunotherapy in OLK is rare, its development is viable and promising, bringing new sights and possibilities in OPMDs treatment (Fig. <xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6"><label>Fig. 6</label><caption xml:lang="en"><p>The illustration of the synergistic PDT/PTT of ITIC-Th NPs after local injection in vivo</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1310_Fig6_HTML.png" id="MO7"/></fig></p></sec></sec><sec id="Sec26" sec-type="conclusions"><title>Conclusions</title><p id="Par76">In summary, we successfully synthesized a novel organic photosensitizer ITIC-Th NPs with superior photodynamic/photothermal properties, excellent biosafety, strong anti-malignant transformation power, which was more convenient and efficient than traditional photosensitizers. The results were also exciting in premalignant animal models. As far as we know, this research was the first interdisciplinary study in the field of near-infrared fluorescence imaging and OLK. Our study provided a promising approach for photosensitizer in OLK's photodynamic and photothermal collaborative treatment, and it was of great benefit to block the canceration process of OLK, which has promising potential for future clinical treatment.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors are grateful to Dr. Ning Duan for helping with the efficacy evaluation of animal experiments. And thanks to Mr. Lei Zhang and Mr. Sheng Chen for their generous help in preparing histopathological sections and immunohistochemical staining scores.</p></ack><sec sec-type="author-contribution"><title>Authors' contributions</title><p>LL: Conceptualization, Data curation, Methodology, Writing—original draft preparation CS: Validation, Software, Methodology, Writing—original draft preparation ZW: Funding acquisition, Visualization HZ: Validation, Visualization ZC: Methodology, Visualization XZ: Formal analysis SH: Investigation, Visualization, Funding acquisition GZ: Investigation, Visualization JR: Investigation Yu Cai: Conceptualization, Project administration, Supervision, Writing—review &amp; editing, Funding acquisition WH: Conceptualization, Resources, Supervision, Writing—review &amp; editing, Funding acquisition. The manuscript was written through contributions of all authors. All authors read and approved the final manuscript.</p></sec><sec><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (82002864), the Natural Science Foundation of Jiangsu Province (BK20191121, BK20210033), the Natural Science Foundation of Zhejiang Province (LQ22F050010), the Project of Invigorating Health Care through Science, Technology, and Education Jiangsu Provincial Medical Youth Talent (QNRC2016121), the China Postdoctoral Science Foundation (2021TQ0145), and the Nanjing Clinical Research Center for Oral Diseases (2019060009).</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>All data generated or analysed during this study are included in this published article.</p></sec><sec sec-type="ethics-statement"><title>Declarations</title><sec id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par77">This study was approved by the Nanjing Stomatological Hospital Ethics Committee (Application Permit Number: 2019NL-029(KS)).</p></sec><sec id="FPar2"><title>Consent for publication</title><p id="Par78">Not applicable.</p></sec><sec id="FPar3" sec-type="COI-statement"><title>Competing interests</title><p id="Par79">The authors declare that they have no competing interests.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piyarathne</surname><given-names>NS</given-names></name><name><surname>Rasnayake</surname><given-names>R</given-names></name><name><surname>Angammana</surname><given-names>R</given-names></name><name><surname>Chandrasekera</surname><given-names>P</given-names></name><name><surname>Ramachandra</surname><given-names>S</given-names></name><name><surname>Weerasekera</surname><given-names>M</given-names></name><name><surname>Yasawardene</surname><given-names>S</given-names></name><name><surname>Abu-Eid</surname><given-names>R</given-names></name><name><surname>Jayasinghe</surname><given-names>JAP</given-names></name><name><surname>Gupta</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">Diagnostic salivary biomarkers in oral cancer and oral potentially malignant disorders and their relationships to risk factors—a systematic review</article-title><source>Expert Rev Mol Diagn</source><year>2021</year><pub-id pub-id-type="doi">10.1080/14737159.2021.1944106</pub-id><pub-id pub-id-type="pmid">34148471</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname><given-names>DI</given-names></name><name><surname>Purkayastha</surname><given-names>M</given-names></name><name><surname>Chestnutt</surname><given-names>IG</given-names></name></person-group><article-title xml:lang="en">The changing epidemiology of oral cancer: definitions, trends, and risk factors</article-title><source>Br Dent J</source><year>2018</year><volume>225</volume><issue>9</issue><fpage>867</fpage><lpage>873</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:STN:280:DC%2BB3cvosVCnsA%3D%3D</pub-id><pub-id pub-id-type="doi">10.1038/sj.bdj.2018.922</pub-id><pub-id pub-id-type="pmid">30412558</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Waal</surname><given-names>I</given-names></name><name><surname>Axéll</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Oral leukoplakia: a proposal for uniform reporting</article-title><source>Oral Oncol</source><year>2002</year><volume>38</volume><issue>6</issue><fpage>521</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/s1368-8375(01)00125-7</pub-id><pub-id pub-id-type="pmid">12167428</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Waal</surname><given-names>I</given-names></name></person-group><article-title xml:lang="en">Historical perspective and nomenclature of potentially malignant or potentially premalignant oral epithelial lesions with emphasis on leukoplakia-some suggestions for modifications</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol</source><year>2018</year><volume>125</volume><issue>6</issue><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.oooo.2017.11.023</pub-id><pub-id pub-id-type="pmid">29396315</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnakulasuriya</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Oral potentially malignant disorders: a comprehensive review on clinical aspects and management</article-title><source>Oral Oncol</source><year>2020</year><volume>102</volume><pub-id pub-id-type="doi">10.1016/j.oraloncology.2019.104550</pub-id><pub-id pub-id-type="pmid">31981993</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DE</given-names></name><name><surname>Burtness</surname><given-names>B</given-names></name><name><surname>Leemans</surname><given-names>CR</given-names></name><name><surname>Lui</surname><given-names>VWY</given-names></name><name><surname>Bauman</surname><given-names>JE</given-names></name><name><surname>Grandis</surname><given-names>JR</given-names></name></person-group><article-title xml:lang="en">Head and neck squamous cell carcinoma</article-title><source>Nat Rev Dis Primers</source><year>2020</year><volume>6</volume><issue>1</issue><fpage>92</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-00224-3</pub-id><pub-id pub-id-type="pmid">33243986</pub-id><pub-id pub-id-type="pmcid">7944998</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iocca</surname><given-names>O</given-names></name><name><surname>Sollecito</surname><given-names>TP</given-names></name><name><surname>Alawi</surname><given-names>F</given-names></name><name><surname>Weinstein</surname><given-names>GS</given-names></name><name><surname>Newman</surname><given-names>JG</given-names></name><name><surname>De Virgilio</surname><given-names>A</given-names></name><name><surname>Di Maio</surname><given-names>P</given-names></name><name><surname>Spriano</surname><given-names>G</given-names></name><name><surname>Pardinas Lopez</surname><given-names>S</given-names></name><name><surname>Shanti</surname><given-names>RM</given-names></name></person-group><article-title xml:lang="en">Potentially malignant disorders of the oral cavity and oral dysplasia: a systematic review and meta-analysis of malignant transformation rate by subtype</article-title><source>Head Neck</source><year>2020</year><volume>42</volume><issue>3</issue><fpage>539</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1002/hed.26006</pub-id><pub-id pub-id-type="pmid">31803979</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Cascarini</surname><given-names>L</given-names></name><name><surname>McCaul</surname><given-names>JA</given-names></name><name><surname>Kerawala</surname><given-names>CJ</given-names></name><name><surname>Coombes</surname><given-names>D</given-names></name><name><surname>Godden</surname><given-names>D</given-names></name><name><surname>Brennan</surname><given-names>PA</given-names></name></person-group><article-title xml:lang="en">How should we manage oral leukoplakia?</article-title><source>Br J Oral Maxillofac Surg</source><year>2013</year><volume>51</volume><issue>5</issue><fpage>377</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.bjoms.2012.10.018</pub-id><pub-id pub-id-type="pmid">23159193</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brothwell</surname><given-names>DJ</given-names></name><name><surname>Lewis</surname><given-names>DW</given-names></name><name><surname>Bradley</surname><given-names>G</given-names></name><name><surname>Leong</surname><given-names>I</given-names></name><name><surname>Jordan</surname><given-names>RC</given-names></name><name><surname>Mock</surname><given-names>D</given-names></name><name><surname>Leake</surname><given-names>JL</given-names></name></person-group><article-title xml:lang="en">Observer agreement in the grading of oral epithelial dysplasia</article-title><source>Community Dent Oral Epidemiol</source><year>2003</year><volume>31</volume><issue>4</issue><fpage>300</fpage><lpage>305</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:STN:280:DC%2BD3szptF2rtw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1034/j.1600-0528.2003.00013.x</pub-id><pub-id pub-id-type="pmid">12846853</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saini</surname><given-names>R</given-names></name><name><surname>Poh</surname><given-names>CF</given-names></name></person-group><article-title xml:lang="en">Photodynamic therapy: a review and its prospective role in the management of oral potentially malignant disorders</article-title><source>Oral Dis</source><year>2013</year><volume>19</volume><issue>5</issue><fpage>440</fpage><lpage>451</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:STN:280:DC%2BC2c%2FlsVWqtw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1111/odi.12003</pub-id><pub-id pub-id-type="pmid">24079944</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">Photodynamic therapy in the treatment of oral leukoplakia: A systematic review</article-title><source>Photodiagnosis Photodyn Ther</source><year>2019</year><volume>25</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXitlens7vK</pub-id><pub-id pub-id-type="doi">10.1016/j.pdpdt.2018.10.023</pub-id><pub-id pub-id-type="pmid">30391342</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafirstein</surname><given-names>G</given-names></name><name><surname>Friedman</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>E</given-names></name><name><surname>Moreno</surname><given-names>M</given-names></name><name><surname>Baumler</surname><given-names>W</given-names></name><name><surname>Fan</surname><given-names>CY</given-names></name><name><surname>Morehead</surname><given-names>K</given-names></name><name><surname>Vural</surname><given-names>E</given-names></name><name><surname>Stack</surname><given-names>BC</given-names></name><name><surname>Jr., Suen, J. Y.,</surname></name></person-group><article-title xml:lang="en">Using 5-aminolevulinic acid and pulsed dye laser for photodynamic treatment of oral leukoplakia</article-title><source>Arch Otolaryngol Head Neck Surg</source><year>2011</year><volume>137</volume><issue>11</issue><fpage>1117</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1001/archoto.2011.178</pub-id><pub-id pub-id-type="pmid">22106236</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SJ</given-names></name><name><surname>Campbell</surname><given-names>B</given-names></name><name><surname>Massey</surname><given-names>B</given-names></name><name><surname>Lynch</surname><given-names>DP</given-names></name><name><surname>Cohen</surname><given-names>EEW</given-names></name><name><surname>Blair</surname><given-names>E</given-names></name><name><surname>Selle</surname><given-names>R</given-names></name><name><surname>Shklovskaya</surname><given-names>J</given-names></name><name><surname>Jovanovic</surname><given-names>BD</given-names></name><name><surname>Skripkauskas</surname><given-names>S</given-names></name><name><surname>Dew</surname><given-names>A</given-names></name><name><surname>Kulesza</surname><given-names>P</given-names></name><name><surname>Parimi</surname><given-names>V</given-names></name><name><surname>Bergan</surname><given-names>RC</given-names></name><name><surname>Szabo</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia</article-title><source>Oral Oncol</source><year>2013</year><volume>49</volume><issue>9</issue><fpage>970</fpage><lpage>976</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXhtVOrtr%2FO</pub-id><pub-id pub-id-type="doi">10.1016/j.oraloncology.2013.05.011</pub-id><pub-id pub-id-type="pmid">23845699</pub-id><pub-id pub-id-type="pmcid">4456032</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Dan</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name></person-group><article-title xml:lang="en">Photodynamic therapy guidelines for the management of oral leucoplakia</article-title><source>Int J Oral Sci</source><year>2019</year><volume>11</volume><issue>2</issue><fpage>14</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXos1Sgsrw%3D</pub-id><pub-id pub-id-type="doi">10.1038/s41368-019-0047-0</pub-id><pub-id pub-id-type="pmid">30971683</pub-id><pub-id pub-id-type="pmcid">6458125</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Hua</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Primary clinical evaluation of photodynamic therapy with oral leukoplakia in chinese patients</article-title><source>Front Physiol</source><year>1911</year><volume>2018</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.3389/fphys.2018.01911</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">The combination of photodynamic therapy and fractional CO2 laser for oral leukoplakia: case series</article-title><source>Photodiagnosis Photodyn Ther</source><year>2020</year><volume>29</volume><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXitF2lsrnM</pub-id><pub-id pub-id-type="doi">10.1016/j.pdpdt.2019.101597</pub-id><pub-id pub-id-type="pmid">31707101</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietruska</surname><given-names>M</given-names></name><name><surname>Sobaniec</surname><given-names>S</given-names></name><name><surname>Bernaczyk</surname><given-names>P</given-names></name><name><surname>Cholewa</surname><given-names>M</given-names></name><name><surname>Pietruski</surname><given-names>JK</given-names></name><name><surname>Dolinska</surname><given-names>E</given-names></name><name><surname>Skurska</surname><given-names>A</given-names></name><name><surname>Duraj</surname><given-names>E</given-names></name><name><surname>Tokajuk</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Clinical evaluation of photodynamic therapy efficacy in the treatment of oral leukoplakia</article-title><source>Photodiagnosis Photodyn Ther</source><year>2014</year><volume>11</volume><issue>1</issue><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXhvVKit7jK</pub-id><pub-id pub-id-type="doi">10.1016/j.pdpdt.2013.10.003</pub-id><pub-id pub-id-type="pmid">24211597</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jerjes</surname><given-names>W</given-names></name><name><surname>Upile</surname><given-names>T</given-names></name><name><surname>Hamdoon</surname><given-names>Z</given-names></name><name><surname>Mosse</surname><given-names>CA</given-names></name><name><surname>Akram</surname><given-names>S</given-names></name><name><surname>Hopper</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Photodynamic therapy outcome for oral dysplasia</article-title><source>Lasers Surg Med</source><year>2011</year><volume>43</volume><issue>3</issue><fpage>192</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1002/lsm.21036</pub-id><pub-id pub-id-type="pmid">21412802</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">Black phosphorus-loaded separable microneedles as responsive oxygen delivery carriers for wound healing</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><issue>5</issue><fpage>5901</fpage><lpage>5908</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3cXns1eku7s%3D</pub-id><pub-id pub-id-type="doi">10.1021/acsnano.0c01059</pub-id><pub-id pub-id-type="pmid">32315159</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Xi</surname><given-names>L</given-names></name><name><surname>Mou</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name></person-group><article-title xml:lang="en">Infection microenvironment-activated nanoparticles for NIR-II photoacoustic imaging-guided photothermal/chemodynamic synergistic anti-infective therapy</article-title><source>Biomaterials</source><year>2021</year><volume>275</volume><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXhtFyis7vJ</pub-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120918</pub-id><pub-id pub-id-type="pmid">34058607</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Ran</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>W</given-names></name></person-group><article-title xml:lang="en">Peroxidase-mimicking evodiamine/indocyanine green nanoliposomes for multimodal imaging-guided theranostics for oral squamous cell carcinoma</article-title><source>Bioact Mater</source><year>2021</year><volume>6</volume><issue>7</issue><fpage>2144</fpage><lpage>2157</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXhtFKjtrfL</pub-id><pub-id pub-id-type="doi">10.1016/j.bioactmat.2020.12.016</pub-id><pub-id pub-id-type="pmid">33511313</pub-id><pub-id pub-id-type="pmcid">7810628</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Conlon</surname><given-names>WJ</given-names></name><name><surname>Hachey</surname><given-names>JS</given-names></name><name><surname>Xin</surname><given-names>J</given-names></name><name><surname>Aras</surname><given-names>O</given-names></name><name><surname>Rodriguez</surname><given-names>EA</given-names></name><name><surname>Ting</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Small ultra-red fluorescent protein nanoparticles as exogenous probes for noninvasive tumor imaging in vivo</article-title><source>Int J Biol Macromol</source><year>2020</year><volume>153</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3cXksFentbw%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.02.253</pub-id><pub-id pub-id-type="pmid">32105698</pub-id><pub-id pub-id-type="pmcid">7493049</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olek</surname><given-names>M</given-names></name><name><surname>Machorowska-Pieniążek</surname><given-names>A</given-names></name><name><surname>Olek</surname><given-names>K</given-names></name><name><surname>Cieślar</surname><given-names>G</given-names></name><name><surname>Kawczyk-Krupka</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Photodynamic therapy in the treatment of oral squamous cell carcinoma - The state of the art in preclinical research on the animal model</article-title><source>Photodiagnosis Photodyn Ther</source><year>2021</year><volume>34</volume><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXhsVaiu7vK</pub-id><pub-id pub-id-type="doi">10.1016/j.pdpdt.2021.102236</pub-id><pub-id pub-id-type="pmid">33639322</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickerson</surname><given-names>EB</given-names></name><name><surname>Dreaden</surname><given-names>EC</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>El-Sayed</surname><given-names>IH</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Pushpanketh</surname><given-names>S</given-names></name><name><surname>McDonald</surname><given-names>JF</given-names></name><name><surname>El-Sayed</surname><given-names>MA</given-names></name></person-group><article-title xml:lang="en">Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice</article-title><source>Cancer Lett</source><year>2008</year><volume>269</volume><issue>1</issue><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1cXhtVagt77O</pub-id><pub-id pub-id-type="doi">10.1016/j.canlet.2008.04.026</pub-id><pub-id pub-id-type="pmid">18541363</pub-id><pub-id pub-id-type="pmcid">3413727</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Pang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">Nanoparticle-based photothermal and photodynamic immunotherapy for tumor treatment</article-title><source>Int J Cancer</source><year>2018</year><volume>143</volume><issue>12</issue><fpage>3050</fpage><lpage>3060</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXhvVSmsb7L</pub-id><pub-id pub-id-type="doi">10.1002/ijc.31717</pub-id><pub-id pub-id-type="pmid">29981170</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JE</given-names></name><name><surname>Jeon</surname><given-names>SJ</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Han</surname><given-names>YW</given-names></name><name><surname>Ko</surname><given-names>EJ</given-names></name><name><surname>Moon</surname><given-names>DK</given-names></name></person-group><article-title xml:lang="en">A 3-fluoro-4-hexylthiophene-based wide bandgap donor polymer for 109% efficiency eco-friendly nonfullerene organic solar cells</article-title><source>Small</source><year>2019</year><volume>15</volume><issue>9</issue><fpage>e1805321</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXit1CgtL4%3D</pub-id><pub-id pub-id-type="doi">10.1002/smll.201805321</pub-id><pub-id pub-id-type="pmid">30698922</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Huo</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Parker</surname><given-names>TC</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Heeger</surname><given-names>AJ</given-names></name><name><surname>Marder</surname><given-names>SR</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name></person-group><article-title xml:lang="en">High-performance electron acceptor with thienyl side chains for organic photovoltaics</article-title><source>J Am Chem Soc</source><year>2016</year><volume>138</volume><issue>14</issue><fpage>4955</fpage><lpage>4961</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC28XkvVahsb0%3D</pub-id><pub-id pub-id-type="doi">10.1021/jacs.6b02004</pub-id><pub-id pub-id-type="pmid">27015115</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Ran</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>W</given-names></name></person-group><article-title xml:lang="en">Organic near-infrared-II nanophotosensitizer for safe cancer phototheranostics and improving immune microenvironment against metastatic tumor</article-title><source>ACS Appl Mater Interfaces</source><year>2021</year><volume>13</volume><issue>3</issue><fpage>3547</fpage><lpage>3558</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXhtFCjtLY%3D</pub-id><pub-id pub-id-type="doi">10.1021/acsami.0c18841</pub-id><pub-id pub-id-type="pmid">33443401</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Hsu</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>CS</given-names></name></person-group><article-title xml:lang="en">Biocompatible D-A semiconducting polymer nanoparticle with light-harvesting unit for highly effective photoacoustic imaging guided photothermal therapy</article-title><source>Adv Funct Mater</source><year>2017</year><volume>27</volume><issue>13</issue><fpage>1605094</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXislGhsLk%3D</pub-id><pub-id pub-id-type="doi">10.1002/adfm.201605094</pub-id><pub-id pub-id-type="pmid">29046623</pub-id><pub-id pub-id-type="pmcid">5642295</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagao</surname><given-names>T</given-names></name><name><surname>Warnakulasuriya</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Fukano</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Shimozato</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: a randomized controlled trial</article-title><source>Int J Cancer</source><year>2015</year><volume>136</volume><issue>7</issue><fpage>1708</fpage><lpage>1717</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXhsVyrsb%2FM</pub-id><pub-id pub-id-type="doi">10.1002/ijc.29156</pub-id><pub-id pub-id-type="pmid">25156040</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>HM</given-names></name><name><surname>Hung</surname><given-names>HY</given-names></name><name><surname>Cheng</surname><given-names>SJ</given-names></name><name><surname>Tsai</surname><given-names>T</given-names></name><name><surname>Chiang</surname><given-names>CP</given-names></name></person-group><article-title xml:lang="en">Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion</article-title><source>Oral Oncol</source><year>2008</year><volume>44</volume><issue>6</issue><fpage>595</fpage><lpage>600</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1cXlvFyht70%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.oraloncology.2007.08.016</pub-id><pub-id pub-id-type="pmid">18203648</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Si</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name></person-group><article-title xml:lang="en">Diketopyrrolopyrrole-triphenylamine organic nanoparticles as multifunctional reagents for photoacoustic imaging-guided photodynamic/photothermal synergistic tumor therapy</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><issue>1</issue><fpage>1054</fpage><lpage>1063</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXitlWg</pub-id><pub-id pub-id-type="doi">10.1021/acsnano.6b07927</pub-id><pub-id pub-id-type="pmid">28033465</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Fan</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>Q</given-names></name></person-group><article-title xml:lang="en">Photocatalysis-mediated drug-free sustainable cancer therapy using nanocatalyst</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>1345</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXltl2isLg%3D</pub-id><pub-id pub-id-type="doi">10.1038/s41467-021-21618-1</pub-id><pub-id pub-id-type="pmid">33649319</pub-id><pub-id pub-id-type="pmcid">7921091</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name></person-group><article-title xml:lang="en">Optical nano-agents in the second near-infrared window for biomedical applications</article-title><source>Chem Soc Rev</source><year>2019</year><volume>48</volume><issue>1</issue><fpage>22</fpage><lpage>37</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXit1Whs77J</pub-id><pub-id pub-id-type="doi">10.1039/c8cs00494c</pub-id><pub-id pub-id-type="pmid">30444505</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>KN</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Fu</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title xml:lang="en">Multifunctional AIE iridium (III) photosensitizer nanoparticles for two-photon-activated imaging and mitochondria targeting photodynamic therapy</article-title><source>J Nanobiotechnology</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>254</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXhvFWqsrrO</pub-id><pub-id pub-id-type="doi">10.1186/s12951-021-01001-4</pub-id><pub-id pub-id-type="pmid">34425820</pub-id><pub-id pub-id-type="pmcid">8381541</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Pennycook</surname><given-names>SJ</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Highly efficient 2D NIR-II photothermal agent with fenton catalytic activity for cancer synergistic photothermal-chemodynamic therapy</article-title><source>Advanced Science</source><year>2020</year><pub-id pub-id-type="doi">10.1002/advs.201902576</pub-id><pub-id pub-id-type="pmid">34437770</pub-id><pub-id pub-id-type="pmcid">7887592</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atchison</surname><given-names>J</given-names></name><name><surname>Kamila</surname><given-names>S</given-names></name><name><surname>Nesbitt</surname><given-names>H</given-names></name><name><surname>Logan</surname><given-names>KA</given-names></name><name><surname>Nicholas</surname><given-names>DM</given-names></name><name><surname>Fowley</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Callan</surname><given-names>B</given-names></name><name><surname>McHale</surname><given-names>AP</given-names></name><name><surname>Callan</surname><given-names>JF</given-names></name></person-group><article-title xml:lang="en">Iodinated cyanine dyes: a new class of sensitisers for use in NIR activated photodynamic therapy (PDT)</article-title><source>Chem Commun (Camb)</source><year>2017</year><volume>53</volume><issue>12</issue><fpage>2009</fpage><lpage>2012</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXht12mt74%3D</pub-id><pub-id pub-id-type="doi">10.1039/c6cc09624g</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">A mxene-based bionic cascaded-enzyme nanoreactor for tumor phototherapy/enzyme dynamic therapy and hypoxia-activated chemotherapy</article-title><source>Nanomicro Lett</source><year>2021</year><volume>14</volume><issue>1</issue><fpage>22</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB38XislWgt7c%3D</pub-id><pub-id pub-id-type="doi">10.1007/s40820-021-00761-w</pub-id><pub-id pub-id-type="pmid">34882297</pub-id><pub-id pub-id-type="pmcid">8660948</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panieri</surname><given-names>E</given-names></name><name><surname>Santoro</surname><given-names>MM</given-names></name></person-group><article-title xml:lang="en">ROS homeostasis and metabolism: a dangerous liason in cancer cells</article-title><source>Cell Death Dis</source><year>2016</year><volume>7</volume><issue>6</issue><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC28XmvFChsLo%3D</pub-id><pub-id pub-id-type="doi">10.1038/cddis.2016.105</pub-id><pub-id pub-id-type="pmid">27277675</pub-id><pub-id pub-id-type="pmcid">5143371</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Ran</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>W</given-names></name></person-group><article-title xml:lang="en">Novel NIR-II semiconducting molecule incorporating sorafenib for imaging guided synergetic cancer phototherapy and anti-angiogenic therapy</article-title><source>J Mater Chem B</source><year>2021</year><volume>9</volume><issue>14</issue><fpage>3235</fpage><lpage>3248</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXnvVaku7w%3D</pub-id><pub-id pub-id-type="doi">10.1039/d1tb00209k</pub-id><pub-id pub-id-type="pmid">33885627</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Bi</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><article-title xml:lang="en">The toxicity of cooking oil fumes on human bronchial epithelial cells through ROS-mediated MAPK, NF-κB signaling pathways and NLRP3 inflammasome</article-title><source>Environ Toxicol</source><year>2022</year><pub-id pub-id-type="doi">10.1002/tox.23465</pub-id><pub-id pub-id-type="pmid">35225430</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Ou</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Tong</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>W</given-names></name></person-group><article-title xml:lang="en">Anti-LDLR modified TPZ@Ce6-PEG complexes for tumor hypoxia-targeting chemo-/radio-/photodynamic/photothermal therapy</article-title><source>J Mater Chem B</source><year>2020</year><volume>8</volume><issue>4</issue><fpage>648</fpage><lpage>654</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXisVaqsb7I</pub-id><pub-id pub-id-type="doi">10.1039/c9tb02248a</pub-id><pub-id pub-id-type="pmid">31898718</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>D</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Panda</surname><given-names>CK</given-names></name><name><surname>Ghose</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>B</given-names></name><name><surname>Sarin</surname><given-names>R</given-names></name><name><surname>Majumder</surname><given-names>PP</given-names></name></person-group><article-title xml:lang="en">Genes and pathways monotonically dysregulated during progression from normal through leukoplakia to gingivo-buccal oral cancer</article-title><source>NPJ Genom Med</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>32</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXhtF2nsbvF</pub-id><pub-id pub-id-type="doi">10.1038/s41525-021-00195-8</pub-id><pub-id pub-id-type="pmid">33980865</pub-id><pub-id pub-id-type="pmcid">8115176</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawaguchi</surname><given-names>H</given-names></name><name><surname>El-Naggar</surname><given-names>AK</given-names></name><name><surname>Papadimitrakopoulou</surname><given-names>V</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>YH</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Hong</surname><given-names>WK</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name><name><surname>Mao</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>3</issue><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1200/jco.2007.13.4072</pub-id><pub-id pub-id-type="pmid">18202409</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>XM</given-names></name><name><surname>Shi</surname><given-names>LJ</given-names></name><name><surname>Zhang</surname><given-names>CP</given-names></name><name><surname>Xu</surname><given-names>LQ</given-names></name><name><surname>Zhou</surname><given-names>ZT</given-names></name></person-group><article-title xml:lang="en">Expression patterns of cancer stem cell markers ALDH1 and CD133 correlate with a high risk of malignant transformation of oral leukoplakia</article-title><source>Int J Cancer</source><year>2013</year><volume>132</volume><issue>4</issue><fpage>868</fpage><lpage>874</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC38XhtFWmsbbP</pub-id><pub-id pub-id-type="doi">10.1002/ijc.27720</pub-id><pub-id pub-id-type="pmid">22782852</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habiba</surname><given-names>U</given-names></name><name><surname>Hida</surname><given-names>K</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>AY</given-names></name><name><surname>Higashino</surname><given-names>F</given-names></name><name><surname>Ito</surname><given-names>YM</given-names></name><name><surname>Ohiro</surname><given-names>Y</given-names></name><name><surname>Totsuka</surname><given-names>Y</given-names></name><name><surname>Shindoh</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">ALDH1 and podoplanin expression patterns predict the risk of malignant transformation in oral leukoplakia</article-title><source>Oncol Lett</source><year>2017</year><volume>13</volume><issue>1</issue><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXhtV2hsrrP</pub-id><pub-id pub-id-type="doi">10.3892/ol.2016.5379</pub-id><pub-id pub-id-type="pmid">28123562</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>LJ</given-names></name><name><surname>Zhang</surname><given-names>ST</given-names></name><name><surname>Wang</surname><given-names>LJ</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>QM</given-names></name></person-group><article-title xml:lang="en">In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><issue>21</issue><fpage>6724</fpage><lpage>6731</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1MXhtlCjsrfE</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-1296</pub-id><pub-id pub-id-type="pmid">19861457</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kujan</surname><given-names>O</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Ravindran</surname><given-names>A</given-names></name><name><surname>Vijayan</surname><given-names>M</given-names></name><name><surname>Farah</surname><given-names>CS</given-names></name></person-group><article-title xml:lang="en">CDK4, CDK6, cyclin D1 and Notch1 immunocytochemical expression of oral brush liquid-based cytology for the diagnosis of oral leukoplakia and oral cancer</article-title><source>J Oral Pathol Med</source><year>2019</year><volume>48</volume><issue>7</issue><fpage>566</fpage><lpage>573</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXhsFCnurrN</pub-id><pub-id pub-id-type="doi">10.1111/jop.12902</pub-id><pub-id pub-id-type="pmid">31172614</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>S-H</given-names></name><name><surname>Han</surname><given-names>E-J</given-names></name><name><surname>Park</surname><given-names>S-Y</given-names></name><name><surname>Jeong</surname><given-names>M-H</given-names></name><name><surname>Seo</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>S-H</given-names></name><name><surname>Sung</surname><given-names>G-J</given-names></name><name><surname>Yoo</surname><given-names>J-Y</given-names></name><name><surname>Yoon</surname><given-names>H-G</given-names></name><name><surname>Choi</surname><given-names>K-C</given-names></name></person-group><article-title xml:lang="en">Serine/threonine kinase 31 promotes PDCD5-mediated apoptosis in p53-dependent human colon cancer cells</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><issue>3</issue><fpage>2649</fpage><lpage>2658</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXhsFOgsbvN</pub-id><pub-id pub-id-type="doi">10.1002/jcp.27079</pub-id><pub-id pub-id-type="pmid">30144069</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Expression and clinical significance of the programmed cell death 5 gene and protein in laryngeal squamous cell carcinoma</article-title><source>J Int Med Res</source><year>2013</year><volume>41</volume><issue>6</issue><fpage>1838</fpage><lpage>1847</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXhs1OksLnN</pub-id><pub-id pub-id-type="doi">10.1177/0300060513498021</pub-id><pub-id pub-id-type="pmid">24265335</pub-id></mixed-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname><given-names>L</given-names></name><name><surname>Mello</surname><given-names>FW</given-names></name><name><surname>Warnakulasuriya</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Tissue biomarkers for predicting the risk of oral cancer in patients diagnosed with oral leukoplakia: a systematic review</article-title><source>Oral Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1111/odi.13747</pub-id><pub-id pub-id-type="pmid">33252790</pub-id></mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnakulasuriya</surname><given-names>S</given-names></name><name><surname>Ariyawardana</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Malignant transformation of oral leukoplakia: a systematic review of observational studies</article-title><source>J Oral Pathol Med</source><year>2016</year><volume>45</volume><issue>3</issue><fpage>155</fpage><lpage>166</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:STN:280:DC%2BC28%2FksVChtw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1111/jop.12339</pub-id><pub-id pub-id-type="pmid">26189354</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Mou</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">Mouse tumor-bearing models as preclinical study platforms for oral squamous cell carcinoma</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>212</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.00212</pub-id><pub-id pub-id-type="pmid">32158692</pub-id><pub-id pub-id-type="pmcid">7052016</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barcessat</surname><given-names>AR</given-names></name><name><surname>Huang</surname><given-names>I</given-names></name><name><surname>Rabelo</surname><given-names>GD</given-names></name><name><surname>Rosin</surname><given-names>FC</given-names></name><name><surname>Ferreira</surname><given-names>LG</given-names></name><name><surname>de Cerqueira Luz</surname><given-names>JG</given-names></name><name><surname>Correa</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">Systemic toxic effects during early phases of topical 4-NQO-induced oral carcinogenesis in rats</article-title><source>J Oral Pathol Med</source><year>2014</year><volume>43</volume><issue>10</issue><fpage>770</fpage><lpage>777</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXhvVKmsbvM</pub-id><pub-id pub-id-type="doi">10.1111/jop.12190</pub-id><pub-id pub-id-type="pmid">24931357</pub-id></mixed-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vered</surname><given-names>M</given-names></name><name><surname>Yarom</surname><given-names>N</given-names></name><name><surname>Dayan</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">4NQO oral carcinogenesis: animal models, molecular markers and future expectations</article-title><source>Oral Oncol</source><year>2005</year><volume>41</volume><issue>4</issue><fpage>337</fpage><lpage>339</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2MXisFKju70%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.oraloncology.2004.07.005</pub-id><pub-id pub-id-type="pmid">15792604</pub-id></mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>C-S</given-names></name><name><surname>Razzo</surname><given-names>BM</given-names></name><name><surname>Fabian</surname><given-names>KPL</given-names></name><name><surname>Chelvanambi</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>S</given-names></name><name><surname>Storkus</surname><given-names>WJ</given-names></name><name><surname>Whiteside</surname><given-names>TL</given-names></name></person-group><article-title xml:lang="en">Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma</article-title><source>Cancer Immunol Immunother</source><year>2019</year><volume>68</volume><issue>7</issue><fpage>1133</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1007/s00262-019-02348-2</pub-id><pub-id pub-id-type="pmid">31139925</pub-id></mixed-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jian</surname><given-names>F</given-names></name><name><surname>Deng</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title xml:lang="en">Analysis of plasma metabolic biomarkers in the development of 4-nitroquinoline-1-oxide-induced oral carcinogenesis in rats</article-title><source>Oncol Lett</source><year>2015</year><volume>9</volume><issue>1</issue><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.3892/ol.2014.2619</pub-id><pub-id pub-id-type="pmid">25435976</pub-id></mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gumus</surname><given-names>R</given-names></name><name><surname>Capik</surname><given-names>O</given-names></name><name><surname>Gundogdu</surname><given-names>B</given-names></name><name><surname>Tatar</surname><given-names>A</given-names></name><name><surname>Altinkaynak</surname><given-names>K</given-names></name><name><surname>Ozdemir Tozlu</surname><given-names>O</given-names></name><name><surname>Karatas</surname><given-names>OF</given-names></name></person-group><article-title xml:lang="en">Low Vitamin D and High Cholesterol facilitate oral carcinogenesis in 4NQO induced rat models via regulating glycolysis</article-title><source>Oral Dis</source><year>2021</year><pub-id pub-id-type="doi">10.1111/odi.14117</pub-id><pub-id pub-id-type="pmid">34954855</pub-id></mixed-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title xml:lang="en">Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis</article-title><source>J Exp Clin Cancer Res</source><year>2019</year><volume>38</volume><issue>1</issue><fpage>299</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXhtlGkurfO</pub-id><pub-id pub-id-type="doi">10.1186/s13046-019-1185-0</pub-id><pub-id pub-id-type="pmid">31291983</pub-id><pub-id pub-id-type="pmcid">6617956</pub-id></mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oghumu</surname><given-names>S</given-names></name><name><surname>Knobloch</surname><given-names>TJ</given-names></name><name><surname>Terrazas</surname><given-names>C</given-names></name><name><surname>Varikuti</surname><given-names>S</given-names></name><name><surname>Ahn-Jarvis</surname><given-names>J</given-names></name><name><surname>Bollinger</surname><given-names>CE</given-names></name><name><surname>Iwenofu</surname><given-names>H</given-names></name><name><surname>Weghorst</surname><given-names>CM</given-names></name><name><surname>Satoskar</surname><given-names>AR</given-names></name></person-group><article-title xml:lang="en">Deletion of macrophage migration inhibitory factor inhibits murine oral carcinogenesis: potential role for chronic pro-inflammatory immune mediators</article-title><source>Int J Cancer</source><year>2016</year><volume>139</volume><issue>6</issue><fpage>1379</fpage><lpage>1390</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC28XpvFCjur0%3D</pub-id><pub-id pub-id-type="doi">10.1002/ijc.30177</pub-id><pub-id pub-id-type="pmid">27164411</pub-id><pub-id pub-id-type="pmcid">4939094</pub-id></mixed-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Chitosan-tripolyphosphate nanoparticles-mediated co-delivery of MTHFD1L shRNA and 5-aminolevulinic acid for combination photodynamic-gene therapy in oral cancer</article-title><source>Photodiagnosis Photodyn Ther</source><year>2021</year><volume>36</volume><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB38XkvFartrs%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.pdpdt.2021.102581</pub-id><pub-id pub-id-type="pmid">34648994</pub-id></mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xuan</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><issue>15</issue><fpage>7360</fpage><lpage>7378</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXitVWlsbrJ</pub-id><pub-id pub-id-type="doi">10.7150/thno.58413</pub-id><pub-id pub-id-type="pmid">34158855</pub-id><pub-id pub-id-type="pmcid">8210602</pub-id></mixed-citation></ref></ref-list></ref-list><app-group><app id="App1" specific-use="web-only"><sec id="Sec27"><title>Supplementary Information</title><p id="Par80"><supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary Information"><media mimetype="application" mime-subtype="msword" xlink:href="MediaObjects/12951_2022_1310_MOESM1_ESM.docx" position="anchor"><caption xml:lang="en"><p><bold>Additional file 1. </bold><bold>Table S1.</bold> Clinic-pathological features of 10 patients with oral leukoplakia. <bold>Table S2.</bold> Histopathological examination results of each group after PTT / PDT.<bold>Figure S1. A</bold> The appearance of ITIC-Th NPs in different media at room temperature after two weeks. The DLS <bold>B</bold> and UV-VIS spectrum <bold>C</bold> of NPs in pH 7.0 and pH 6.5. <bold>Figure S2.</bold><bold> A</bold> Temperature change curves of ITIC-Th NPs solution ([ITIC-Th NPs] = 75 μg/mL) under 660nm laser irradiation.<bold> B</bold> The time constant for heat transfer was determined to be τs = 232 s. <bold>C</bold> The electron spin resonance (ESR) result of NPs. <bold>Figure S3.</bold><bold>A</bold> The scheme of the experiment. <bold>B</bold> The near-infrared fluorescence imaging of NPs solution under different thickness covers of beef. <bold>Figure S4.</bold><bold>A</bold>–<bold>C</bold> The cell activity assay of HaCaT, RAW264.7, and THP-1 with different concentrations of ITIC-Th NPs solutions evaluated by CCK-8. (D) Leuk-1 cells treated with hematoporphyrin for 24h, with or without laser. <bold>Figure S5.</bold> The ITIC-Th NPs with fluorescence in Leuk-1 and tumor cells (CAL 27) with different incubation times. Scale bar:100 μm. <bold>Figure S6.</bold><bold>A</bold> The quantitative analysis of Live/Dead cells stain in Figure 4D. ***p &lt; 0.001. <bold>B</bold> The quantitative analysis of Figure 4E. **p &lt; 0.01. <bold>Figure S7.</bold><bold>A</bold> Expression of biomarkers in representative OLK tissues was detected by immunohistochemistry (Scale bar = 100 μm). <bold>B</bold> Quantitative analysis of Fig A. (n = 5, mean ± SD, *p &lt; 0.05, **p &lt; 0.01). <bold>C</bold> The negative control without primary antibodies (Scale bar = 100 μm). <bold>Figure S8.</bold> PDT/PTT Schematic illustration of treatment in rats.</p></caption></media></supplementary-material></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>OLK</term><def><p id="Par3">Oral leukoplakia</p></def></def-item><def-item><term>PSs</term><def><p id="Par4">Photosensitizers</p></def></def-item><def-item><term>PDT</term><def><p id="Par5">Photodynamic therapy</p></def></def-item><def-item><term>ITIC-Th NPs</term><def><p id="Par6">ITIC-Th nanoparticles</p></def></def-item><def-item><term>PTT</term><def><p id="Par7">Photothermal therapy</p></def></def-item><def-item><term>ROS</term><def><p id="Par8">Reactive oxygen species</p></def></def-item><def-item><term>4NQO</term><def><p id="Par9">4-Nitroquinoline 1-oxide</p></def></def-item><def-item><term>OSCC</term><def><p id="Par10">Oral squamous cell carcinoma</p></def></def-item><def-item><term>OPMDs</term><def><p id="Par11">Oral potentially malignant disorders</p></def></def-item><def-item><term>WHO</term><def><p id="Par12">World Health Organization</p></def></def-item><def-item><term>OLK</term><def><p id="Par13">Oral leukoplakia</p></def></def-item><def-item><term>5-ALA</term><def><p id="Par14">5-Aminolevulinic acid</p></def></def-item><def-item><term>PpIX</term><def><p id="Par15">Porphyrin IX</p></def></def-item><def-item><term>NIR</term><def><p id="Par16">Near-infrared</p></def></def-item><def-item><term>A-D-A</term><def><p id="Par17">Acceptor–donor-acceptor</p></def></def-item><def-item><term>THF</term><def><p id="Par18">Tetrahydrofuran</p></def></def-item><def-item><term>ATCC</term><def><p id="Par19">American Type Culture Collection</p></def></def-item><def-item><term>SOSG</term><def><p id="Par20">Singlet Oxygen Sensor Green</p></def></def-item><def-item><term>DPBF</term><def><p id="Par21">1, 3-Diphenylisobenzofuran</p></def></def-item><def-item><term>CCK-8</term><def><p id="Par22">Cell Counting Kit-8</p></def></def-item><def-item><term>ALDH1</term><def><p id="Par23">Aldehyde dehydrogenase isoform 1</p></def></def-item><def-item><term>PDCD5</term><def><p id="Par24">Programmed cell death 5</p></def></def-item><def-item><term>PDPN</term><def><p id="Par25">Podoplanin</p></def></def-item><def-item><term>TEM</term><def><p id="Par26">Transmission electron microscope</p></def></def-item><def-item><term>DLS</term><def><p id="Par27">Dynamic light scattering</p></def></def-item><def-item><term>K-SFM</term><def><p id="Par28">Keratinocyte serum-free medium</p></def></def-item><def-item><term>HaCaT</term><def><p id="Par29">Human immortalized keratinocyte line</p></def></def-item><def-item><term>DMEM</term><def><p id="Par30">Dulbecco's modified Eagle's medium</p></def></def-item><def-item><term>FBS</term><def><p id="Par31">Fetal Bovine Serum</p></def></def-item><def-item><term>DCFH-DA</term><def><p id="Par32">2, 7-Dichlorodi-hydrofluorescein diacetate</p></def></def-item><def-item><term>SD</term><def><p id="Par33">Sprague–Dawley</p></def></def-item><def-item><term>H&amp;E</term><def><p id="Par34">Hematoxylin and eosin</p></def></def-item><def-item><term>EDS</term><def><p id="Par35">Energy-dispersive spectroscopy</p></def></def-item><def-item><term>ESR</term><def><p id="Par36">Electron spin resonance</p></def></def-item><def-item><term>HNSCC</term><def><p id="Par37">Head and neck squamous cell carcinoma</p></def></def-item><def-item><term>CDK</term><def><p id="Par38">Cyclin-dependent kinase</p></def></def-item><def-item><term>CR</term><def><p id="Par39">Complete clinical response</p></def></def-item><def-item><term>LN</term><def><p id="Par40">Lymph node</p></def></def-item></def-list></glossary><notes notes-type="Misc"><title>Publisher's Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></notes></back></article></records><facets><facet name="subject"><facet-value count="1">Biotechnology</facet-value><facet-value count="1">Chemistry</facet-value><facet-value count="1">Molecular Medicine</facet-value><facet-value count="1">Nanotechnology</facet-value></facet><facet name="keyword"><facet-value count="1">Nanomedicine</facet-value><facet-value count="1">Oral leukoplakia</facet-value><facet-value count="1">Photodynamic therapy</facet-value><facet-value count="1">Tumor</facet-value></facet><facet name="pub"><facet-value count="1">Journal of Nanobiotechnology</facet-value></facet><facet name="year"><facet-value count="1">2022</facet-value></facet><facet name="country"><facet-value count="1">China</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
